documents incorporated reference specified portions registrant 's definitive proxy statement filed commission pursuant regulation connection annual meeting incorporated reference part iii report based closing price per share excludes shares registrant 's common stock held executive officers directors stockholders whose ownership exceeds common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrant gilead sciences inc annual report table contents part item business item properties item legal proceedings item submission matters vote security holders part ii item market registrant 's common stock related stockholder matters item selected financial data item management 's discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management item certain relationships related transactions item controls procedures part iv item exhibits financial statement schedules reports form k signatures certifications rights various trademarks copyrights trade names used business including following gilead gilead sciences hepsera leaf shield design leaf shield design bw liver design tablet design bw tablet design color viread vistide daunoxome ambisome tamiflu registered trademark belonging hoffmannla roche report also includes trademarks service marks trade names companies part item business forwardlooking statements risk factors report includes forwardlooking statements particular statements expectations beliefs plans objectives assumptions future events performance contained incorporated reference report based forwardlooking statements current expectations future events believe expectations reasonable forwardlooking statements inherently subject risks uncertainties many beyond control actual results may differ materially suggested forwardlooking statements various reasons including discussed report heading risk factors affect gilead given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof undertake specifically decline obligation update statements publicly announce results revisions statements reflect future events developments used report unless otherwise indicated us refers gilead subsidiaries overview gilead sciences inc biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases worldwide six products currently marketed us five also marketed countries worldwide research clinical programs focused antiinfectives including antivirals antifungals endeavor grow existing portfolio products proprietary clinical development programs internal discovery programs active product acquisition inlicensing strategy worldwide headquarters foster city california european headquarters paris france incorporated delaware june january completed acquisition outstanding stock triangle pharmaceuticals inc triangle whollyowned subsidiary gilead aggregate preliminary purchase price million including cash paid outstanding stock fair value options assumed estimated direct transaction costs employee termination costs triangle develops drug candidates antiviral area particular focus potential therapies hiv including aids hepatitis b virus triangle 's portfolio consists several drug candidates clinical trials including emtricitabine treatment hiv infection emtricitabine treatment hepatitis b amdoxovir treatment hiv infection clevudine treatment hepatitis b triangle filed marketing applications emtricitabine treatment hiv united states european union products viread approved sale sold us us commercial team use combination antiretroviral agents treatment hiv infection european union european commercial team use combination antiretroviral agents treatment hiv infection patients experiencing early virological failure ambisome approved sale sold countries treatment lifethreatening fungal infections countries prevention infections market ambisome major countries europe copromote ambisome us fujisawa healthcare inc fujisawa hepsera approved sale sold us us commercial team treatment chronic hepatitis b hepsera received marketing approval european union march tamiflu approved sale sold corporate partner hoffmannla roche roche countries including us european union prevention treatment influenza vistide approved sale sold us us commercial team gilead 's exus partner pharmacia corporation pharmacia countries treatment cytomegalovirus cmv retinitis patients aids daunoxome approved sale sold countries treatment aidsrelated kaposi 's sarcoma sold us us commercial team independent distributors abroad earned revenues million sales royalties products amount sales viread generated aggregate product sales royalty revenues million total revenues sales ambisome generated aggregate product sales royalty revenues million total revenues earned revenues sales royalties products us million million million outside us earned revenues sales royalties products million million million viread tenofovir disoproxil fumarate viread oral formulation nucleotide analogue reverse transcriptase inhibitor tenofovir df dosed day part combination therapy treat hiv infection adults drug works blocking reverse transcriptase enzyme involved replication hiv sell viread us us commercial team major european countries european commercial team see commercial operations us food drug administration fda approved viread marketing us october european agency evaluation medicinal products emea granted similar approval european union february us viread approved use combination antiretroviral agents treatment hiv infection indication based analyses plasma hiv rna levels cd cell counts controlled study viread weeks duration study controlled doseranging study viread weeks duration study studies conducted treatmentexperienced adults evidence hiv viral replication despite ongoing antiretroviral therapy studies patients previously received antiretroviral therapy antiretroviralnave patients ongoing february reported week data ongoing threeyear randomized doubleblind clinical trial study designed compare efficacy safety combination treatment regimen viread lamivudine tc efavirenz combination treatment regimen stavudine dt lamivudine efavirenz antiretroviralnave patients hiv infection data study demonstrates treatmentnave patients received viread experienced substantially less lipodystrophy lower elevations fasting cholesterol triglyceride levels well improved levels limb fat weight gain achieving similar reductions hiv viral load increases cd cell counts compared received stavudine adverse events reported less two percent patients included rash bacterial infection depression fever pneumonia low discontinuation rate approximately percent arm study week data supplements week results study submitted fda support use viread patients prior hiv therapy intend submit week data potential inclusion us european labels predict whether fda emea accept interpretation data approve label indicating viread use patients prior hiv therapy based data approval week data study recommended committee proprietary medicinal products cpmp february one major challenges treating hivinfected patients drug resistance many existing therapies treating hiv infection aids rely similarlydesigned drug processes patients developed resistance one drug often develop resistance drugs within class believe viread approved regulatory authorities offers advantages approved hiv treatments available data shown patients developed resistance viread viread effective treating patients developed resistance therapies certain however resistance data may obtain upon completion phase clinical trials show similar resistance characteristics week data study data obtained limited phase clinical trials another major concern hiv treatment convenience dosing combination therapies positive impact require hivinfected patients take numerous drugs drugs require multiple doses every day many timing dietary restrictions results inconvenience patients also contributes patients missing doses adhering therapy viread approved administered oncedaily oral pill schedule may appealing hivinfected patients physicians hiv competitive landscape becoming crowded complicated treatment trends continue evolve twenty branded antihiv drugs currently sold us many others advance stages clinical development see competition exclusive worldwide license patent rights related technology viread institute organic chemistry biochemistry part academy sciences czech republic rega stichting vzw together iocbrega obligated pay percentage net revenues sales viread us european union countries product approved patent protection iocbrega see academic consulting relationshipsiocbrega ambisome amphotericin b liposome injection ambisome proprietary liposomal formulation amphotericin b amphotericin b powerful antifungal agent known ability treat serious invasive fungal infections caused various fungal species infections generally life threatening particularly patients depressed immune systems due aggressive chemotherapy regimens stem cell organ transplant hiv infection ambisome treatment also serious side effects including kidney toxicity studies show however delivering amphotericin b proprietary liposomal formulation ambisome reduces rate severity kidney toxicity injectionrelated reactions allows patients receive higher doses amphotericin b ambisome approved sale countries including us european union rest europe australia canada several countries middle east latin america asia countries ambisome approved including us authorized topromote ambisome empirical treatment fungal infections ie treatment patients strong suspicion without definite confirmation exists potentially lifethreatening invasive fungal infection remaining countries ambisome approved sale approved use either firstline treatment serious invasive fungal infection secondline treatment conventional amphotericin b therapy fails conventional amphotericin b tolerated finally ambisome approved number countries various indications example cryptococcal meningitis aids patients prophylaxis liver transplant patients visceral leishmaniasis us copromote ambisome fujisawa us commercial team agreement fujisawa entitles us percentage revenues generated sales provides fujisawa purchases ambisome us manufacturing cost see collaborative relationshipsfujisawa major european countries australia sell ambisome international commercial teams certain countries sell ambisome independent distributors revenues ambisome europe expect case foreseeable future licensed commercial rights ambisome japan sumitomo pharmaceuticals co ltd sumitomo exchange royalties generated activities however ambisome yet approved sale japan ambisome faces strong competition several current competitors expected competitors whose treatments late stage clinical trials see competition competition current expected competitors likely erode revenues receive sales ambisome hepsera adefovir dipivoxil hepsera oral formulation nucleotide analogue hbv dna polymerase inhibitor adefovir dipivoxil dosed day treat chronic hepatitis b hepatitis b caused highly contagious hepatitis b hbv virus cause acute liver failure patients develop chronic hepatitis b infection many years lead complications cirrhosis liver cancer liver failure approximately patients result death according recent estimates world health organization centers disease control million people worldwide million people us chronic hepatitis b one million deaths attributable chronic hepatitis b worldwide year one ten leading causes death worldwide hepsera disables hbv interfering activity enzyme known hbv polymerase necessary virus replicate applications us european union marketing authorizations included data two separate phase clinical trials designed evaluate safety effectiveness hepsera mg dosage treating patients hepatitis b virus phase trials designed randomized doubleblind placebocontrolled studies clinical sites us canada europe australia southeast asia study evaluated hepsera treating patients test positive hbv e antigen common type hepatitis b us trial study evaluated hepsera treating patients type hepatitis b known precore mutant hepatitis b common southeast asian mediterranean countries weeks adefovirassociated resistance mutations identified hepatitis b patients treated clinical trials suggests development resistance hepsera hepatitis b patients may delayed infrequent consequently believe hepsera 's resistance profile could make important drug treating chronic hepatitis b certain however resistance data may obtain continuing phase clinical trials hepsera continue show resistance characteristics hepsera approved sale us treatment chronic hepatitis b adults evidence active viral replication either evidence persistent elevations serum aminotransferases alt ast histologically active liver disease us commercial team sells hepsera us march applied approval emea hepsera treatment chronic hepatitis b european union approval emea recommended cpmp november received march plan sell hepsera major european union countries european commercial team vaccine available prevent transmission hbv effective people already become chronically infected hbv expect vaccine becomes widely available incidence new hepatitis b infections decrease however even advances prevention hepatitis b individuals suffering chronic hepatitis b represent patient pool significant risk morbidity mortality due underlying chronic viral infection chronic hepatitis b common china southeast asia december received clinical trials permit initiate phase clinical trials china commenced clinical trials june licensed rights commercialize hepsera solely treatment hepatitis b china korea japan taiwan rest asia latin america certain territories glaxosmithkline gsk part approval commence phase clinical trials china hepsera granted class designation hepsera ultimately approved sale china would give gsk years market exclusivity hepsera respect competitors may otherwise able begin clinical development adefovir dipivoxil following approval receiving chinese government 's approval phase study given approval move forward phase program began patient enrollment december several existing therapies treating patients infected hbv compete hepsera treatments represent significant competition hepsera see competition exclusive worldwide license patent rights related technology adefovir dipivoxil iocbrega pay percentage net revenues sales hepsera iocbrega countries product patent protection including us member states european union addition pay small variable percentage net revenues us sales hepsera md anderson cancer center see academic consulting relationships tamiflu oseltamivir phosphate tamiflu oral pill treatment prevention influenza b tamiflu class prescription drugs called neuraminidase inhibitors act disabling common strains flu virus preventing virus spreading patient used approved treatment influenza tamiflu shown reduce duration flu adults average reduce severity flu symptoms incidence secondary infections taken approved prevention influenza studies shown tamiflu effective preventing development flu tamiflu approved countries treatment influenza including us japan european union treatment influenza childrenand adults tamiflu also approved us european union prevention influenza adolescents adults developed tamiflu roche roche exclusive right manufacture sell tamiflu subject obligation pay us percentage net revenues roche generates tamiflu sales date roche 's sales tamiflu significantly expectations moreover roche experienced problems manufacturing distribution tamiflu reduced net sales royalty based material effect revenues see collaborative relationshipsroche several products available treat flu time shown effective safe neuraminidase inhibitors see competition tamiflu marketed alternative influenza vaccinations believe influenza vaccinations remain effective method preventing flu vistide cidofovir injection vistide antiviral medication treatment cmv retinitis patients aids cmv retinitis condition characterized lesions form patient 's retina affects persons weakened immune systems common patients aids left untreated cmv retinitis lead blindness vistide approved sale us european union several countries demand vistide low product revenues immaterial us commercial team sells vistide us outside us pharmacia exclusive right sell vistide pharmacia pays us percentage revenues generates sales vistide see collaborative relationshipspharmacia active agent vistide cidofovir considered part us government strategy dealing potential bioterrorism attacks involving smallpox lifethreatening highly communicable infectious disease laboratory tests cidofovir demonstrated activity strains virus causes smallpox current clinical trials diluted smallpox vaccine conducted national institute allergy infectious diseases cidofovir considered potential treatment vaccinia infection adverse reaction sometimes caused smallpox vaccine additionally us national institutes health holds ind allows emergency use cidofovir smallpox outbreaks without marketing approval fda know efficacy cidofovir might emergency use side effects may appear use cidofovir smallpox also predict whether us countries ' governments may stockpile vistide treatment smallpox daunoxome daunorubicin citrate liposome injection daunoxome liposomal formulation anticancer agent daunorubicin firstline therapy treating patients suffer certain types hiv associated kaposi 's sarcoma disease characterized widely disseminated lesions skin mucous membranes lymph nodes viscera life threatening patients suffering aids daunoxome approved sale us countries sell daunoxome us sell abroad independent distributors demand daunoxome low product revenues immaterial products clinical trials emtricitabine hiv acquired emtricitabine result acquisition triangle completed january nucleoside analogue emtricitabine shown inhibitor hiv hbv replication laboratory studies emtricitabine antiviral agent hiv strains obtained geographically diverse set hiv infected patients laboratory studies shown emtricitabine shares crossresistance patterns lamivudine common resistance mutation two agents also reverses resistance hiv azt cases four phase clinical studies emtricitabine completed one collaboration agence nationale de recherches sur le sida anrs france one studies study ftc compared emtricitabine mg onceaday stavudine mg twiceaday combination didanosine mg onceaday efavirenz mg onceaday patients without previous antiretroviral therapy july study unblinded recommendation independent data safety monitoring board dsmb established provide oversight study interim results evaluated study 's dsmb showed emtricitabine arm statistically superior stavudine arm primary secondary endpoints safety efficacy eightyseven percent patients onceaday emtricitabine arm persistent virologic response six months compared twicedaily stavudine arm patients emtricitabine arm also significant improvements immunologic function view compelling difference favor emtricitabine arm dsmb recommended study unblinded patients offered regimen containing emtricitabine application marketing approval emtricitabine submitted treatment hiv us september european union december applications accepted review us fda advised us date review july emtricitabine hepatitis b emtricitabine shown inhibitor hepatitis b virus replication patients chronically infected hbv currently phase clinical development emtricitabine treatment chronic hepatitis b development activities undertaken emtricitabine treatment hiv also used assessment emtricitabine treatment hepatitis b amdoxovir acquired amdoxovir result acquisition triangle completed january amdoxovir purine dioxolane nucleoside may offer advantages nucleosides currently market activity drug resistant viruses exhibited laboratory studies early triangle initiated two phase clinical trials amdoxovir august fda placed clinical development program amdoxovir partial clinical hold result concerns lenticular opacities possible side effect characterized clouding lens eye extent amdoxovir increased occurrence lenticular opacities patients receiving amdoxovir unknown patients clinical studies benefiting amdoxovir new studies involving patients failed treatments contained drug currently approved class antihiv medications require amdoxovir theirregimens may continue treatment discussions fda regarding partial clinical hold planned clevudine acquired clevudine result acquisition triangle completed january clevudine pyrimidine nucleoside analogue shown potent inhibitor hepatitis b virus replication laboratory studies november triangle initiated phase studies currently conducting phase clinical trials clevudine treatment chronic hepatitis b chronic toxicology studies completed reproductive toxicology studies progress gs gs novel nucleotide analogue reverse transcriptase inhibitor processed body yields tenofovir active chemical yielded viread within cells chemical composition gs however may allow cross cell membranes easily viread leading greater potency viread first quarter began phase clinical trials gs treatment hiv infection research development research scientists foster city san dimas california durham north carolina engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs therapeutic focus areas life threatening infectious diseases total research development rd expenses million compared million million nucleotide analogues scientists working proprietary nucleotide analogues develop treatments viral infections compounds treat viral infections interfering activity certain enzymes necessary virus grow believe small molecule nucleotide analogues offer advantages therapeutics first molecules demonstrated ability work infected uninfected cells could enable us develop drugs treat patient infected virus also prevent healthy person becoming infected first place second drugs developed using molecules shown treatment activity patient longer periods time available drugs could enable us develop drugs require less frequent dosing thus convenient patients hiv protease inhibitors evaluating number small molecule compounds known protease inhibitors potential treatment hiv infection protease inhibitors act interfering activity protease enzyme like reverse transcriptase necessary replication hiv conducted number preclinical experiments compounds demonstrated potent antiviral activity lead candidate gs currently undergoing extensive preclinical evaluations antiviral research undertaking additional research area treatment viral diseases many efforts focus potential targets hiv therapeutic drugs liposomes also scientists focused applying proprietary liposomal drug delivery technology develop safer effective convenient drugs liposomes submicroscopic hollow spheres drugs packed believe research supports belief influence way compounds released distributed body placing liposomes turn improve safety treatment benefits compounds commercial operations us international commercial sales operations marketing subsidiaries united kingdom germany italy spain france portugal greece australia commercial teams promote sell viread hepsera ambisome us viread ambisome europe australia ambisome also sold fujisawa us sell vistide daunoxome us commercial partner pharmacia sells vistide outside us sell daunoxome outside us independent distributors commercial partner roche promotes sells tamiflu everywhere sold commercial teams promote viread hepsera direct field contact physicians hospitals clinics healthcare providers involved treatment patients hiv viread chronic hepatitis b hepsera also promote ambisome infectious disease specialists hospitals home health care providers cancer specialists international commercial operations europe australia european commercial team supported medical operational financial regulatory manufacturing human resources personnel located primarily european headquarters paris france us australian commercial teams supported worldwide headquarters foster city california countries outside us agreements thirdparty distributors including distributors certain countries marketing operations promote sell distribute viread ambisome daunoxome international distribution agreements generally provide distributor exclusive right sell viread ambisome daunoxome particular country several countries specified period time january announced program pursuant selling viread cost countries africa countries designated least developed countries united nations taking steps ensure viread product sold program used serve patients developing world diverted markets see international distributionto support expand commercialization viread hepsera significantly increased sales force us devoting additional marketing resources us improve coverage healthcare professionals treating hivinfected hbvinfected patients also significantly increased size commercial operations europe manage commercialization viread anticipated commercialization hepsera european union current intention retain commercial rights hepsera market directly distributors us canada europe australia new zealand turkey april entered licensing agreement gsk gsk received rights commercialize hepsera asia latin america africa certain territories agreement retained rights hepsera us canada eastern western europe australia new zealand turkey gsk received exclusive rights develop hepsera solely treatment hepatitis b countries significant include china korea japan taiwan gsk full responsibility development commercialization hepsera territories us viread hepsera vistide returnable original unopened containers one year beyond expiration date damaged received customer customers may return ambisome daunoxome shelf life expired product damaged defective customer receives ambisome approved shelf life months us months european countries daunoxome shelf life weeks us european countries viread shelf life months us european union hepsera shelf life months us additionally certain governmental agency customers state aids drug assistance programs entitled receive discounts required provide rebates state medicaid programs date returns rebates discounts material financial results fujisawa establishes return policy ambisome north america roche establishes return policy tamiflu end flu season significant returns tamiflu roche reduces net sales royalty roche based collaborative relationships part business strategy establish collaborations companies assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring companies products rights products technologies complementary business accounting relationships found note consolidated financial statements included report existing collaborative relationships follows anadys pharmaceuticals inc june entered collaboration anadys pharmaceuticals inc discover novel antiviral compounds addition access fees milestone payments subject limitations gilead pay anadys royalties products developed research collaboration archemix corporation october entered agreement archemix corporation archemix agreement granted archemix exclusive sublicense selex technology identify aptamers subject exclusion development areas rights already granted forfeited rights selex technology derive license us university license equity holdings inc ulehi successor university technology corporation predecessor university research corporation financial terms agreement archemix provide lump sum payments us totaling million archemix made payments also received warrants purchase archemix stock agreement required agreements ulehi shared portion cash payments warrants ulehi see academic consulting relationshipsuniversity license equity holdings inc bukwang pharm ind co ltd february triangle entered acquired part acquisition triangle license agreement bukwang pharm ind co ltd bukwang pursuant received exclusive license bukwang 's rights clevudine use hepatitis b field well human antiviral applications license includes countries world except korea license obligated make milestones royalty payments bukwang including annual minimum royalty beginning third year first fda registration granted fdaapproved product incorporating clevudine technology glaxosmithkline april entered licensing agreement gsk giving exclusive rights commercialize hepsera solely treatment hepatitis b asia latin america certain territories addition fees milestone payments contract revenues gsk required pay us percentage revenue generate sales hepsera licensed territories agreement gsk required enter clinical commercial supply agreements gsk would required arrange supply clinical commercial requirements fully burdened cost subject reasonable forecasting ordering procedures agreement gsk expires individual country basis later patent expiration ten years first commercial sale particular country addition gsk right electively terminate agreement months notice gilead subject fee elective termination circumstances early term agreement eyetech pharmaceuticals march entered agreement eyetech pharmaceuticals inc eyetech relating product named macugen developed treatment agerelated macular degeneration amd diabetic macular edema dme gilead invented compound upon macugen based nx using selex technology licensed gilead ulehi see academic consulting relationshipsuniversity license equity holdings inc gilead licensed nx eyetech developed macugen license gilead eyetech required pay us fees milestone payments well percentage revenue generate worldwide sales macugen agreement eyetech expires upon later ten years first commercial sale product developed date last patent expires agreement eyetech granted pfizer sublicense relating macugen december december connection sublicense gilead agreed enter license pfizer terms contained agreement eyetech rochein entered collaboration agreement roche granting roche exclusive worldwide rights tamiflu well proprietary influenza neuraminidase inhibitors december received license fees milestone payments roche totaling million relating execution agreement regulatory filings approvals tamiflu roche also funded research development costs tamiflu including reimbursement us million period january december agreement roche responsible pricing manufacturing promoting selling tamiflu worldwide basis pays us percentage net revenues sales tamiflu subject reduction certain defined manufacturing costs agreement roche terminates individual country basis later patent expiration ten years first commercial sale particular country addition roche right terminate agreement entirety individual country basis prior expiration time upon months notice fujisawa entered agreement granting fujisawa exclusive right promote sell ambisome canada primary responsibility promote sell ambisome us gilead copromoter fujisawa pays us approximately fujisawa 's net revenues sales ambisome us reserved right promote sell ambisome rest world pay fujisawa net revenues ambisome sales significant asian markets including japan korea taiwan china india manufacture ambisome sold worldwide sell ambisome fujisawa sale us price equal cost manufacture product sale canada price equal cost manufacture product plus specified percentage agreement fujisawa terminates last patent covering ambisome us japan expires osi pharmaceuticals december sold osi pharmaceuticals osi pipeline clinical stage oncology products related intellectual property well boulder colorado operations consideration assets received osi million cash shares osi common stock additionally osi pay us additional million either cash combination cash osi common stock upon achievement osi certain milestones related development nx advanced oncology product candidates separately manufacturing agreement osi agreed produce osi liposomal formulations two products including nx manufacturing facility san dimas california pharmacia entered agreement pharmacia relating vistide agreement pharmacia exclusive right market sell vistide countries outside us subject payment us percentage net revenues required sell pharmacia bulk vistide maintain vistide patents agreement pharmacia expires individual country basis upon patent expiration ten years first commercial sale countries product covered patent addition pharmacia may terminate agreement whole upon six months notice upon notice individual country basis three months applying marketing approval competitive product sumitomo entered agreement sumitomo gave sumitomo exclusive right develop market ambisome japan addition milestone payments sumitomo required pay us percentage revenue generate japanese sales ambisome ambisome approved sale japan would manufacture ambisome sale sumitomo japan price would charge sumitomo supply ambisome percentage revenues would required pay us would determined price ambisome japan agreement sumitomo terminates later patent expiration japan ten years first commercial sale japan termination agreement cubist pharmaceuticals cidecin september jointly announced cubist pharmaceuticals inc termination licensing agreement commercialization cidecin daptomycin injection oral formulation daptomycin terminated license agreement executed january granted us exclusive commercialization rights products european countries following regulatory approval terms termination agreement owe future payments cubist cubist reacquired european rights products academic consulting relationships supplement research development efforts part regular business enter arrangements universities medical research institutions arrangements often provide us rights patents patent applications technology owned institutions return payments fees relating use rights emory university university georgia research foundation inc emtricitabine april triangle obtained acquired part acquisition triangle exclusive worldwide license emory university 's rights purified forms emtricitabine use hiv hepatitis b fields obligated make certain milestone royalty payments emory including annual minimum royalties beginning third year first fda registration granted antihiv product incorporating emtricitabine technology us third year first registration granted antihepatitis b product incorporating emtricitabine technology certain major market countries hiv hepatitis b indications respectively triangle began paying license maintenance fees development milestones yet achieved may emory gsk settled litigation pending united states district court relating emtricitabine became exclusive licensee us foreign patents patent applications filed burroughs wellcome co use emtricitabine treat hepatitis b license settlement agreements emory also given access development clinical data drug substance held gsk relating emtricitabine may emory gsk shire pharmaceuticals group plc shire settled worldwide patent disputes involving lamivudine emtricitabine theterms settlement emory received exclusive license shire shire 's patents relating emtricitabine methods use manufacture shire gsk received exclusive licenses emory 's patents relating lamivudine terms license agreement emory automatically acquired exclusive sublicense shire patents relating emtricitabine granted terms settlement thereby resolving previously pending patent disputes regarding emtricitabine amdoxovir march triangle entered acquired part acquisition triangle license agreement emory university georgia research foundation inc ugrf pursuant received exclusive worldwide license emory 's ugrf 's rights series nucleoside analogues including amdoxovir dxg ie active antihiv agent use hiv hepatitis b fields obligated make milestone royalty payments emory ugrf march triangle began paying license maintenance fees development milestones yet achieved beginning third year first fda registration granted fdaapproved product incorporating amdoxovir technology required pay emory ugrf minimum annual royalty august triangle resolved outstanding patent disputes involving amdoxovir shire terms settlement emory ugrf received exclusive license shire 's patent rights covering amdoxovir methods use manufacture terms license agreement acquired exclusive sublicense rights exchange obligation pay shire incremental royalty future amdoxovir sales settlement agreement emory ugrf gilead granted shire exclusive license patent rights bch methods use manufacture license agreements emory terminate upon later patent expiration expiration obligation pay royalties addition right terminate agreement entirety respect one indications hiv hbv one countries prior expiration time upon days notice md anderson cancer center entered agreement md anderson cancer center relating hepsera agreement currently pay md anderson cancer center percentage net revenues based upon sales hepsera agreement md anderson cancer center terminates later patent expiration ten years first commercial sale iocbrega entered agreements iocbrega relating viread hepsera vistide agreements received iocbrega exclusive right manufacture use sell nucleotide compounds covered agreements currently pay net revenues based upon sales viread hepsera vistide iocbrega agreements iocbrega terminate individual country basis later patent expiration ten years first commercial sale addition iocbrega may terminate licenses particular product key market absence commercial sales product within months regulatory approval university license equity holdings inc ongoing collaborative arrangement university license equity holdings inc ulehi technology holding company university colorado boulder relating selex technology identify aptamers arrangement ulehi granted us present future rights inventions covered patents patent applications selex technology improvements selex technology makes discovers oligonucleotides molecules makes using selex technology computer software related selex technology required pay ulehi certain variable royalties based revenues generated sales products derived using selex technology developing world collaborations bill melinda gates foundation family health international october entered agreement bill melinda gates foundation family health international fhi provide viread fhi 's multinational clinical trial evaluating viread 's effectiveness method reducing risk hiv infection among sexually active adults regularly exposed hiv clinical trials conducted fhi funded million threeyear grant gates foundation dart study november entered collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conducted mrc antiretroviral hiv therapy africa trial called dart trial development antiretroviral therapy africa aimed studying clinical versus laboratory monitoring practices structured treatment interruptions versus continuous antiretroviral therapy adults hiv infection subsaharan africa provide viread cost dart study institute one world health january entered agreement institute one world health pursuant provide ambisome cost phase clinical trial evaluating ambisome treatment visceral leishmaniasis paromomycin india greatest global burden visceral leishmaniasis clinical trial conducted institute one world health partnership world health organization international distribution various agreements distributors europe asia latin america middle east africa grant distributors exclusive right sell ambisome cases daunoxome particular country countries specified period time agreements also provide collaborative efforts us distributor obtaining regulatory approval product particular country marketing product country agreements establish price distributor must pay product require us deliver quantities product ordered distributor entered similar distribution agreements viread countries promote sell directly january announced program pursuant supply viread cost countries africa countries designated least developed countries united nations humanitarian effort recognition extreme impact hiv disease resourcepoor countries world 's cases hiv located countries taking steps ensure viread product sold program used serve patients developing world diverted markets manufacturing ambisome daunoxome manufacture ambisome daunoxome commercial quantities two separate adjacent facilities san dimas california medicines control agency united kingdom fda approved commercial production ambisome daunoxome facility produced import ambisome daunoxome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union elsewhere use commercially available materials equipment manufacture products currently obtain amphotericin b use manufacture ambisome daunorubicin hcl distearoylphosphatidylcholine use manufacture daunoxome cholesterol use manufacture ambisome daunoxome single approved suppliers ambisome sold freezedried product currently freezedry ambisome san dimas manufacturing facility also use third party freeze dry additional product given current projections growth ambisome demand sufficient capacity meet future demand also option installing additional freezedrying capacity san dimas additional supply become necessary prove unable install additional freeze drying capacity san dimas locate appropriate third parties meet need ability meet increased ambisome demand would diminished manufacturing liposomal products particularly complex process new liposomal product develop require unique complex variations manufacturing process antiviral products contract third parties manufacture antiviral drugs clinical commercial purposes including viread hepsera vistide emtricitabine amdoxovir clevudine manufacture viread tablets single contract manufacturer us european union sales distribution territories addition second contract manufacturer europe european union distributed product approved respective agencies obtained qualification us seeking qualification european union two contract manufacturers active ingredient hepsera one contract manufacturer final hepsera drug product commercial supply seeking qualify second supplier january roche announced due production problems liquid suspension form tamiflu approved treatment children young one yearold available however liquid suspension form tamiflu returned market time flu season production issues affect availability tablet form tamiflu adults adolescents years older japan flu season particularly severe roche 's sublicensee chugai corporation unable meet heightened demand satisfactorily january chugai issued press release attributing failure part manufacturing problems problems japan reduced net sales royalty roche based date production commercialization issues material effect earnings expect material effect earnings future entered agreement abbott manufacture emtricitabine bulk drug substance final drug product us currently seeking qualification abbott us european union contract manufacturer also seeking qualification european union second contract manufacturer emtricitabine bulk drug substance abbott recent history violations current good manufacturing practice regulations cited us fda working towards corrections fda consent decree fda conducted preapproval inspection abbott new drug application emtricitabine issued form observation abbott december january abbott submitted response form observation fda deems abbott 's response form observation inadequate abbott unable supply initial launch quantities emtricitabine timely manner emtricitabine launch could delayed two suppliers approved fda european union manufacture cidofovir used vistide single fda emea approved supplier final vistide drug product commercialscale manufacturing facilities antiviral products current plans establish facilities future antiviral products need develop additional manufacturing capabilities establish additional third party suppliers order manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities products approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future antiviral products ability conduct largescale clinical trials meet customer demand commercial products would adversely affected believe technology use manufacture products compounds proprietary antiviral products disclosed necessary aspects technology contract manufacturers enable manufacture products compounds us agreements manufacturers intended restrict using revealing technology certain manufacturers comply restrictions addition manufacturers could develop technology related work perform us may need manufacture products compounds could required enter agreement manufacturer wanted use technology allow another manufacturer use technology manufacturer could refuse allow us use technology could demand terms use technology acceptable believe compliance material environmental regulations related manufacture products patents proprietary rights patents proprietary rights important business properly designed enforceable patent difficult ourcompetitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection us internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy number patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows actual estimated expiration dates us europe primary patents patents may issue pending applications cover compounds marketed products product candidates us patent expiration european patent expiration products viread hepsera ambisome tamiflu vistide daunoxome product candidates emtricitabine amdoxovir clevudine applications patents pending patents applications issue would patent protection dates indicated would instead rely patents expire earlier example european patent viread issue patents expire provide protection patents covering viread hepsera vistide emtricitabine clevudine amdoxovir held third parties acquired exclusive rights patents agreements parties see collaborative relationships academic consulting relationships patents cover active ingredients ambisome daunoxome instead hold patents liposomal formulations compounds also protect formulations trade secrets patent filings covering forms hepsera china certain asian countries although applications pending various asian countries including china relate specific forms formulations hepsera asia major market hbv therapies may obtain patents compounds many years obtain marketing approval limits time prevent companies developing compounds therefore reduces value product however apply patent term extensions example extensions patents vistide granted us number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third party allowing us use technology certain required could obtain license thirdparty technology could obtain one reasonable cost able obtain required license could adversely affected patent applications confidential least period time including sometimes us patent issues may pending patent applications patents eventually issue prevent us developing selling certain products unless obtain license use patented technology patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation reexamination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection addition pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products developing also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements would adequate remedies breach trade secrets otherwise become known independently discovered competitors research development agreements inventions discovered certain cases become jointly owned us corporate partner cases become exclusive property one us difficult determine owns particular invention disputes could arise regarding inventions competition products development programs target number diseases conditions including viral fungal bacterial infections many commercially available products diseases large number companies institutions spending considerable amounts money resources todevelop additional products treat diseases current products compete available products based primarily efficacy safety tolerability acceptance doctors patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability various modes dosing products market future also compete products offered competitors competitors introduce data shows improved characteristics products improve increase marketing efforts simply lower price products sales products could decrease also certain products may develop future compare favorably products offered competitors existing future products compare favorably new products developed competitors ability competitive also depends upon ability attract retain qualified personnel obtain patent protection otherwise develop proprietary products processes secure sufficient capital resources substantial period takes develop product viread hiv competitive landscape becoming crowded complicated treatment trends continue evolve growing number antihiv drugs currently sold advance stages clinical development branded drugs available us zerit stavudine dt sold bristolmyers squibb bms fixed combination products combivir azt tc trizivir azt tc abc sold gsk represent direct competition viread companies process launching formulations existing drugs indicated fda oncedaily oral dosing include gsk 's mg dose epivir tc bms 's new extended release formulation zerit antiretroviral product candidates expected enter market next years include atazanivir qd protease inhibitor bms fuzeon injectable integrase inhibitor rochetrimeris gsk also pursuing oncedaily dose ziagen abacavir well new fixed dose combination ziagen epivir companies competing hiv therapeutic category pfizer merck boehringeringelheim abbott laboratories ambisome ambisome faces strong competition several current expected competitors current competitors include conventional amphotericin b made bms numerous generic manufacturers caspofungin product developed merck marketed cancidas us caspofungin elsewhere voriconazole developed pfizer marketed vfend lipidbased amphotericin b products approved us throughout europe including abelcet sold enzon corp us canada japan elan corporation 's marketing distribution partners countries amphotec sold intermune pharmaceuticals inc presently unapproved expected competitors include class treatments called echinocandins including fujisawa 's micafungin received marketing approval japan october submission regulatory approval us canada anidulafungin versicor inc product candidate evaluated multiple latestage clinical trials finally schering plough developing noxafil posaconazole currently phase trials competition current expected competitors eroded likely continue erode revenues receive sales ambisome hepsera hepsera faces significant competition existing therapies treating patients infected hbv significantly epivirhbv lamivudine developed collaboration shire pharmaceuticals sold gsk major countries throughout north south america europe asia orally administered nucleoside analogue inhibits hbv dna polymerase introna interferon alfab sold schering plough major countries throughout north south america europe asia introna injectable drug immunomodulatory effects hepsera also faces competition clinicalstage candidates including bristolmyers squibb 's entecavir idenix 's ldt two oral nucleoside analogues currently phase trials competition includes roche 's pegasys pegylated interferon alfaa currently studied chronic hepatitis btamiflu tamiflu competes relenza antiflu drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder addition biocryst pharmaceuticals developing neuraminidase inhibitor antiflu drug peramivir represent significant competition fda approves drug may administered oncedaily pill opposed tamiflu must taken twice daily treatment certain tamiflu compare favorably drug based performance price length dosing side effects criteria vistide vistide competes number drugs also treat cmv retinitis including ganciclovir sold intravenous oral formulations roche ocular implant bausch lomb incorporated valganciclovir also marketed roche foscarnet intravenous drug sold astrazeneca formivirsen drug injected directly eye sold cibavision daunoxome daunoxome competes expected compete number drugs approved awaiting approval treatment kaposi 's sarcoma us europe including doxil product ortho biotech like daunoxome sold liposomal formulation number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together biopharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs anticipate face increased competition future competitors introduce new products market new technologies become available determine existing products new products competitors develop effective effectively marketed sold develop competitive products could render technology products obsolete noncompetitive recover money resources used develop products government regulation operations activities subject extensive regulation numerous government authorities us countries us drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion products result regulations product development product approval process expensive time consuming fda must approve drug sold us general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug 's potential safety benefits submit data fda investigational new drug application ind seeking approval test compound humans clinical trials fda accepts investigational new drug application study drug human clinical trials determine drug safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug given small number healthy human subjects patients test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug given limited patient population determine effect drug treating disease best dose drug possible side effects safety risks drug phase compound appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials longterm involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug uncommon drug appears promising phase clinical trials fail rigorous reliable phase clinical trials fda approval process believe data phase clinical trials show adequate level safety effectiveness file new drug application nda fda seeking approval sell drug particular use fda review nda often hold public hearing independent advisory committee expert advisors asks additional questions regarding drug committee makes recommendation fda binding fda generally followed fda fda agrees compound required level safety effectiveness particular use allow us sell drug us use unusual however fda reject application believes drug safe enough effective enough believe data submitted reliable conclusive point process development drug could stopped number reasons including safety concerns lack treatment benefit certain clinical trials conducting including viread emtricitabine hiv infection hepsera chronic hepatitis b conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require us complete additional testing provide additional data information improve manufacturing processes procedures facilities require extensive postmarketing testing surveillance monitor safety benefits product candidates determine new drug application contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug approvals also withdrawn fda believe complying regulatory standards problemsare uncovered occur approval addition obtaining fda approval drug manufacturing facilities drug sell including companies manufacture drugs us well must approved fda subject periodic inspections fda foreign establishments manufacture products sold us must also approved fda subject periodic regulatory inspection manufacturing facilities located california including san dimas facility foster city facility also must licensed state california compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs may designated fast track products fda may eligible priority six month review accelerated approval case viread drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds research development activities eliminate risk accidental contamination injury materials misuse accidents involving materials could lead significant litigation fines penalties drugs also subject extensive regulation outside us european union centralized approval procedure authorizes marketing product countries european union includes major countries europe procedure used decentralized system approval one country european union used obtain approval another country european union simplified application process approval centralized procedure pricing reimbursement approvals also required countries vistide viread approved european union centralized procedure viread hiv drug reviewed accelerated approval european union hepsera received traditional review emtricitabine pricing reimbursement insurance companies health maintenance organizations hmos thirdparty payors governments seek limit amount charge drugs example certain foreign markets pricing negotiations often required obtain approval product us expect continue number federal state proposals implement drug price control addition managed care organizations becoming common us continue seek lower drug prices announcement proposals efforts cause stock price lower proposals adopted revenues could decrease ability sell drugs also depends availability reimbursement governments private insurance companies governments insurance companies often demand rebates predetermined discounts list prices expect products developing particularly aids indications subject reimbursement issues certain products obtain regulatory approval reimbursed government insurance companies regulatory approval prices generally required foreign countries particular certain countries condition approval product agreement seller sell product certain price country past required price reductions connection product approval certain regulatory authorities future establish lower prices regulatory action reducing price products one country practical effect requiring us reduce prices countries european governments notably germany italy implemented considering legislation would require pharmaceutical companies sell products subject reimbursement mandatory discount mandatory discounts would reduce revenue receive drug sales certain developing countries significantly affected hiv aids parallel importing generic competition may occur adversely affect revenues sales market share viread management changes march announced john f milligan phd promoted senior vice president chief financial officer reporting directly ceo part restructuring combined responsibility corporate functions support strategic financial communications technological planning broadened senior management role corporate development finance corporate communications information technology groups centralized leadership dr milligan addition announced time completion organization changes including alignment manufacturing group san dimas operational areas reporting mark l perry executive vice president operations establishing paris france headquarters european operations employees february approximately fulltime employees believe good relations employees website website address wwwgileadcom make available free charge website annual report quarterly reports form q current reports form k amendments reports soon reasonably practicable filing providing hyperlink edgar website directly reports risk factors affect gilead evaluating business carefully consider following risks addition information report following risks could materially adversely affect business operating results financial condition viread maintain increase market acceptance results operations suffer rely sales viread significant portion operating income viread faces extremely competitive marketplace number drugs treat hiv infection aids currently sold advanced stages clinical development including products currently sold us among companies significant competitors hivaids market gsk bristolmyers squibb roche pfizer merck boehringeringelheim abbott laboratories competitors potential competitors substantially greater resources resources include greater experience promoting marketing hiv drugs superior product development capabilities financial scientific manufacturing marketing managerial human resources order viread continue success maintain expand position marketplace competitors ' drugs viread 's market penetration may limited particularly use treatmentnave patients given data data supporting marketing approvals reflects use viread treatmentexperienced patient population although obtained data safety efficacy viread treatment nave patients regulatory authorities may allow us include data labeling viread marketing efforts unsuccessful include information viread 's use treatmentnave patients viread 's labeling data may unsuccessful convincing physicians prescribe viread treatmentnave patients government reimbursers private insurance companies may pay viread prescribed patients prior hiv therapy viread maintain increase market acceptance results operations suffer significant reduction viread ambisome hepsera sales would significantly reduce operating income could require us scale back manufacturing operations reduce sales force viread product sales years ended december million million total revenues respectively expect product sales viread constitute substantial part total revenues foreseeable future ambisome sales years ended december million million million total revenues expect revenues sales ambisome continue provide material portion total product revenues hepsera product sales began september year ended december approximately million total revenues expect product sales hepsera constitute substantial part total revenues foreseeable future accordingly foreseeable future expect continue rely heavily sales viread ambisome hepsera support existing manufacturing sales infrastructure provide operating income fund significant portion administrative research development expenditures significant reduction sales viread ambisome hepsera whether result introduction competitive products otherwise would hurt business would scale back manufacturing operations reduce sales force safety issues arise marketed products could significantly reduce limit sales adversely affect results operations data support marketing approvals products including viread ambisome hepsera form basis safety warnings product labels obtained controlled clinical trials limited duration case viread limited postapproval use following approval products used longer periods time many patients taking numerous medicines underlying health problems monitored dosing compliance new safety issues reported postmarketing use rule contributory role products may required provide additional warnings labels narrow approved indications could reduce market acceptance products example observe kidney toxicity clinical trials viread kidney toxicity reported postapproval use viread viread label updated include warning serious safety issues marketed products arise could face potential product liability claims sales products could halted us regulatory authorities similarly discontinued development adefovir dipivoxil mg treatment hiv infection due safety benefit concerns arising studies doubleblind placebo controlled studies adefovir dipivoxil mg demonstrated safety efficacy treatment patients chronic hepatitis b studies shown adefovir dipivoxil significantly effective hbv hiv allowing us use lower dose mg adefovir dipivoxil hepsera used treatment hiv infection mg dose adefovir dipivoxil used hepsera associated significant kidney toxicity clinical trials date patients preexisting kidney problems taking drugs known cause kidney toxicity fda granted marketing approval hepsera certain results phase clinical studies hepsera demonstrate satisfaction regulatory agencies including european union hepsera safe effective treatment chronic hepatitis b hepsera new drug may gain significant market acceptance hepsera new drug faces competitive marketplace currently two drugs sold us treatment chronic hepatitis b potential drugs late stages clinical development competitors potential competitors substantially greater resources resources include greater experience promoting marketing pharmaceuticals including hbv drugs superior product development capabilities greater financial scientific manufacturing marketing managerial human resources order hepsera successful establish marketplace competitors ' drugs early determine hepsera achieve significant market acceptance welldeveloped market generally accepted treatment strategy hepatitis b never marketed sold drug treatment chronic hepatitis b might successful may able develop therapeutic market effectively long term use hepsera may reveal safety issues development resistance hepsera patients marketing efforts unsuccessful hepsera turns safety resistance issues may unsuccessful convincing physicians prescribe hepsera patients government reimbursers private insurance companies may pay hepsera hepsera gain significant market acceptance expected future results operations suffer fiscal year first full year operating profitability may able maintain profitability sustainable basis never profitable operating basis full year may continue profitable future expect merger triangle reduce earnings effect earnings increase earnings although certain estimates correct december accumulated deficit approximately million losses resulted principally expenses associated research development programs lesser extent sales general administrative expenses operating results may adversely affected reduced sales products increased marketing development expenses acquisitions products companies triangle unprofitable time acquisition result risks described report develop drugs treat hiv infection aids related conditions therefore changes regulatory commercial environment hiv infection aids therapies could harm businessseveral products products development address hiv infection aids related conditions products include viread emtricitabine hiv infection aids vistide cmv retinitis daunoxome hivassociated kaposi 's sarcoma develop products based upon current policy current marketplace hiv infection aids therapies well prediction future policy future marketplace therapies business subject substantial risk policies markets change quickly unpredictably ways could impair ability maintain regulatory approval commercial acceptance products operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis achieve continued compliance could delay commercialization products products develop must approved marketing sale regulatory authorities subject extensive regulation fda comparable regulatory agencies countries continuing clinical trials ambisome viread hepsera currently approved additional uses anticipate conduct variety clinical trials file marketing approval additional products next several years products may fail receive marketing approval timely basis certain hepsera approved european union regulatory authorities countries us whether hepsera receive marketing approvals countries significant limitations placed use certain emtricitabine approved us european union whether marketing approvals significant limitations use also certain able obtain regulatory approvals necessary expand commercial efforts new markets failures delays limitations well regulatory changes actions recalls could delay commercialization products adversely affect results operations addition even products marketed products manufacturers subject continual review later discovery previously unknown problems products manufacturing production thirdparty manufacturers may result restrictions products manufacture products including withdrawal products market fail comply applicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution results clinical trials uncertain may support regulatory approval products required demonstrate safety effectiveness products develop intended use extensive preclinical studies clinical trials order obtain regulatory approval products results preclinical early clinical studies always accurately predict results later large scale clinical trials several reasons including preliminary results may indicative effectiveness clinical trials may achieve desired result clinical trials may reveal unduly harmful side effects may show drugs less effective drugs delivery systems desired indications even successfully completed largescale clinical trials may result marketable products several reasons including potential products shown safe effective regulatory authorities disagree results design studies trials potential products difficult develop commercially viable products number companies industry suffered setbacks advanced clinical trials despite promising results earlier trials end may unable develop additional marketable products delays enrolling patients developing suitable protocols clinical trials could increase costs delay regulatory approvals rate completion clinical trials depend rate patient enrollment substantial competition enroll patients clinical trials drugs development competition delayed clinical trials past addition recent improvements existing drug therapy particularly hiv hepatitis b may make difficult us enroll patients clinical trials patient population may choose enroll clinical trials sponsored companies choose alternative therapies delays planned patient enrollment result increased development costs delays regulatory approvals clinical trials must carried protocols acceptable regulatory authorities committees responsible clinical studies sites studies conducted may delays preparing protocols receiving approval may delay either start finish clinical trials addition feedback regulatory authorities results earlier stage clinical studies might require modifications delays later stage clinical trials types delays result increased development costs delayed regulatory approvals approximately half product sales occur outside us currency fluctuations may impair financial results significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar equivalent sales negatively impact financial condition results operations effective january began use foreign currency forward contracts hedge percentage forecasted international sales primarily denominated euro currency also hedge portion accounts receivable balances denominated foreign currencies reduces eliminate exposure currency fluctuations date sale recorded date cash collected additionally mitigate impact currency rate fluctuations cash outflows certain foreign currencydenominated raw materials purchases enter foreign exchange forward contracts hedge foreign currency denominated accounts payable although use forward contracts reduce impact foreign currency fluctuations future results certain efforts successful fluctuations could adversely affect results operationswe face credit risks international accounts receivable subject credit risk accounts receivable related european product sales european product sales government owned supported customers greece spain portugal italy subject significant payment delays due government funding reimbursement practices significant changes occur reimbursement practices european governments government funding becomes unavailable financial position results operations would adversely affected product development expenses cause operating expenses fluctuate quarter quarter clinical trials required regulatory approval products extremely expensive difficult accurately predict control amount timing expenses quarter quarter uneven unexpected activity programs causes operating results fluctuate quarter quarter depend relationships companies sales marketing performance revenues failure maintain relationships would negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance include collaborations fujisawa sumitomo ambisome gsk hepsera roche tamiflu pharmacia vistide certain countries rely international distributors sales ambisome viread european countries intend rely international distributors sales hepsera relationships also involve clinical development products partners reliance collaborative relationships poses number risks including able control whether corporate partners devote sufficient resources programs products disputes may arise future respect ownership rights technology developed corporate partners disagreements corporate partners could lead delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenue existing products including viread hepsera ambisome tamiflu could decline january roche announced due production problems liquid suspension form tamiflu approved treatment children young one year old available however liquid suspension form tamiflu returned market time flu season production issues affect availability tablet form tamiflu adults adolescents years older japan flu season particularly severe roche 's sublicensee chugai corporation unable meet heightened demand satisfactorily january chugai issued press release attributing failure part manufacturing problems problems japan reduced net sales royalty roche based april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories including asia africa latin america include major markets hepsera china japan taiwan korea success hepsera territories depend almost entirely efforts gsk receive royalties gsk equal percentage net sales made gsk gsk fails devote sufficient resources succeed developing commercializing hepsera territories potential revenues sales hepsera may substantially reduced existing products products development may accepted physicians insurers patients ability products achieve sustain market acceptance countries approved marketing depend scope regulatory approvals whether government authorities managed care organizations adequately reimburse patients use products addition need convince medical patient advocacy community effectiveness products treating disease safety products administered patients advantages products competitive products physicians patients patient advocates payors medical community general may accept use products may develop products accepted results operations suffer many companies targeting diseases conditions competitive products companies could significantly reduce themarket acceptance products products development programs target number diseases conditions including viral infections fungal infections many commercially available products diseases certain products wellestablished therapies generated substantial sales addition large number companies institutions conducting wellfunded research development activities directed developing treatments diseases products currently market development competitors could make technology products obsolete noncompetitive expect competition treatment diseases increase future new products enter market advanced technologies become available also competing license acquire technology companies plan supply viread cost certain developing countries reduce viread 's gross profit margin could give rise unforeseen liabilities launching distribution program pursuant supply viread cost countries africa countries designated least developed countries united nations receive profit viread supply program reduce viread product 's gross profit margin amount reduction depend upon volume viread flows program predict certainty additionally supply distribution drugs resourcepoor environment complicated undertaking program develops could face unforeseen challenges risks could give rise unforeseen liabilities existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental third party payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement government authorities thirdparty payors increasingly challenging price medical products services particularly innovative new products therapies resulted lower average sales prices example majority sales ambisome vistide daunoxome significant percentage sales viread hepsera subject reimbursement government agencies resulting significant discounts list price rebate obligations business may adversely affected increase us international pricing pressures pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general us recent years new legislation proposed federal state levels would effect major changes health care system either nationally state level proposals included prescription drug benefit proposals medicare beneficiaries introduced congress although us federal reform legislation states enacted health care reform legislation federal state developments possible although predict exact nature legislative health care reforms results operations could adversely affected reforms europe success hepsera approved sale tamiflu viread also depend largely obtaining maintaining government reimbursement europe many european countries including united kingdom france patients reluctant pay prescription drugs pocket also expect success products development particularly europe depend ability obtain reimbursement even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis addition many international markets governments control prices prescription pharmaceuticals markets regulatory marketing approval received pricing negotiations governmental authorities take another six twelve months longer sales competing products attempts gain market share introductory pricing programs competitors could also require us lower prices countries could adversely affect results operations foreign governments passed considering legislation require us sell products subject reimbursement mandatory discount product revenues could reduced imports countries products available lower prices sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly viread agreed provide cost countries africa countries designated least developed countries united nations revenues would adversely affected addition european union required permit cross border sales allows buyers countries governmentapproved prices products relatively high purchase products legally countries must sold lower prices crossborder sales adversely affect revenues may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others rights us foreign issued patents filed continue file patent applications us abroad relating technologies risk however patents may issue applications patents sufficient protect technology patent applications confidential least period time sometimes us patent issues result may know competitors filed patent applications technology covered pending applications also certain first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera although dohave applications pending various asian countries relate various forms formulations adefovir dipivoxil asia major market therapies hepatitis b indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale commercial value product may limited addition patents may provide adequate protection certain countries africa asia including china competitors may file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even successful success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties certain would able obtain alternative technologies required license even obtain technologies licenses certain terms would reasonable fail obtain licenses alternative technologies may unable develop commercialize products addition use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors countries may required grant compulsory licenses hiv products face generic competition hiv products number developing countries government officials groups suggested pharmaceutical companies make drugs hiv infection available low cost cases governmental authorities indicated pharmaceutical companies patents might enforceable prevent generic competition major pharmaceutical companies greatly reduced prices hiv drugs certain developing countries certain countries permit enforcement patents sales viread countries could reduced generic competition alternatively governments countries could require grant compulsory licenses allow competitors manufacture sell versions viread countries thereby reducing viread sales could respond governmental concerns reducing prices viread situations results operations could adversely affected manufacturing problems could delay product shipments regulatory approvals depend third parties perform manufacturing obligations effectively timely basis third parties fail perform required could impair ability deliver products timely basis cause delays clinical trials applications regulatory approval events could harm competitive position viread hepsera vistide rely third parties manufacture bulk drug substance final drug product clinical commercial purposes example roche responsible manufacturing tamiflu january roche announced due production problems liquid suspension form tamiflu approved treatment children young one year old available however liquid suspension form tamiflu returned market time flu season production issues affect availability tablet form tamiflu adults adolescents years older japan flu season particularly severe roche 's sublicensee chugai corporation unable meet heightened demand satisfactorily january chugai issued press release attributing failure part manufacturing problems problems japan reduced net sales royalty roche based additionally emtricitabine seeking qualification abbott us european union contract manufacturer bulk drug substance final drug product also seeking qualification european union second contract manufacturer emtricitabine bulk drug substance abbott recent history violations current good manufacturing practice regulations cited fda working towards corrections fda consent decree fda conducted preapproval inspection abbott new drug application emtricitabine issued form observation abbott december january abbott submitted response form observation fda deems abbott 's response form observation inadequate abbott unable supply initial launch quantities emtricitabine timely manner emtricitabine launch could delayed manufacture ambisome daunoxome facilities san dimas california formulation manufacturing facilities san dimas california although manufacturing facility ireland performs certain quality control testing labeling packaging use third parties alternate contract suppliers fill freeze dry certain batches product event natural disaster including earthquake equipment failure strike difficulty may unable replace manufacturing capacity timely manner would unable manufacture ambisome daunoxome meet market needs may able obtain materials necessary manufacture products many materials utilize operations made one facility example depend single suppliers high quality amphotericin b daunorubicin hcl distearoylphosphatidylcholine high quality cholesterol used manufacture one liposomal products suppliers key components materials must named new drug application filed fda product significant delays occur qualification new supplier required supplies suppliers interrupted reason may unable ship viread ambisome hepsera vistide daunoxome supply products development clinical trials limited experience manufacturing existing products may need develop additional manufacturing capacity products potential future products potential products development need develop production technologies use larger scale order conduct clinical trials produce products commercial sale acceptable cost certain able implement developments successfully manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations fda 's current good manufacturing practices extensive regulations governing manufacturing processes stability testing recordkeeping quality standards addition manufacturing operations subject routine inspections regulatory agencies similar regulations effect countriesour business may give rise product liability claims covered insurance indemnity agreements testing manufacturing marketing use viread ambisome hepsera tamiflu vistide daunoxome well products development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others successful product liability claim us could require us pay substantial amounts could impair financial condition ability clinically test market products additionally required governmental regulations test products even sold used patients result tests may required may determine recall products already market subsequent testing product recalls may increase potential exposure product liability claims internal research programs efforts obtain rights new products third parties may yield potential products clinical development long term success depends ability either identify internal research programs potential product candidates may developed new pharmaceutical products obtain new products product candidates licenses third parties significant portion research conduct involve new unproven technologies research programs identify product candidates require substantial technical financial human resources whether candidates identified research programs may appear promising route identifying potential product candidates yet fail yield product candidates clinical development number reasons including research methodology used may successful identifying potential product candidates potential product candidates may study shown unduly harmful side effects characteristics indicate unlikely effective drugs may unable develop larger scale manufacturing methods efficient costeffective capable meeting stringent regulatory standards others may hold intellectual property rights prevent us developing making selling certain products may unable obtain suitable product candidates products third parties number reasons including may unable purchase license compounds terms would allow us make appropriate return product competitors may unwilling assign license product rights us may unable identify suitable products product candidates within areas expertise product candidates acquire may approved regulatory authorities due problems safety effectiveness unable develop suitable potential product candidates internal research programs obtain rights new products third parties future revenue growth suffer use hazardous materials chemicals viruses radioactive compounds exposes us potential liabilities research development involves controlled use hazardous materials chemicals viruses various radioactive compounds although believe safety procedures handling disposing materials comply standards prescribed state federal regulations completely eliminate risk accidental contamination injury materials event accident could held liable significant damages fines risks related triangle acquisition january emtricitabine may receive marketing approval single agent could prevent delay commercial sale coformulation viread emtricitabine submitted applications marketing approval emtricitabine treatment hiv infection us european union ability obtain marketing approval coformulation viread emtricitabine depend emtricitabine receiving marketing approval single agent treatment hiv infection regulatory authorities us european union countries may grant marketing approval emtricitabine conclude safe efficacious intended use addition regulatory authorities european union require new products sufficient efficacy safety advantages currently marketed products extensive preclinical toxicity data authorities may conclude emtricitabine approvable single agent emtricitabine similar chemical level epivir gsk 's lamivudine product already marketed treatment hiv infection available data indicates products comparable safety efficacy profiles emtricitabine receive marketing approval single agent may unable obtain marketing approval coformulation viread emtricitabine may conduct lengthy expensive clinical trials coformulation order obtain approvals proposed coformulation viread emtricitabine may technically possible may effective safe may approved regulatory authorities intend develop commercialize coformulation viread emtricitabine achieving anticipated synergies potential benefits co formulation significant motivations behind merger triangle depend successfully creating obtaining marketing approval co formulation viread emtricitabine expect emtricitabine receives marketing approval major requirement obtaining marketing approval coformulation viread emtricitabine would clinical study showing coformulation emtricitabine viread biologically equivalent emtricitabine viread administered together separate formulations need chemistry manufacturing bioequivalence package shows co formulated tablet gives exposure viread emtricitabine two drugs given individually uncertain whether possible bring coformulation market emtricitabine approved marketing regulatory authorities may approved might require additional clinicaltrials order obtain regulatory approval addition physical combination emtricitabine viread may technically feasible costeffective even two drugs coformulated regulatory authorities may approve coformulation may require additional clinical trials granting marketing approval requirement clinical trials delay failure developing commercializing coformulation emtricitabine viread would material adverse effect business financial condition results operations successfully integrate triangle operations business adversely affected integrating gilead triangle complex timeconsuming process prior merger gilead triangle operated independently business corporate culture locations employees systems gilead triangle operate combined organization begin utilizing common information communication systems operating procedures financial controls human resource practices including benefits training professional development programs may substantial difficulties costs delays involved integration gilead triangle may include distracting management business combined company potential incompatibility corporate cultures potential inability coordinate research development efforts successfully costs delays implementing common systems procedures operating combined company three sites us nine international sites one factors may increase operating costs lower anticipated financial performance addition combined company may lose corporate partners distributors suppliers manufacturers employees many factors also outside control company achieving anticipated synergies potential benefits underlying two companies ' reasons merger depend successful integration two companies failure integrate gilead triangle successfully would material adverse effect business financial condition results operations unable manufacture emtricitabine successfully reasonable cost potential future results could suffer manufactured emtricitabine familiar manufacturing process emtricitabine completion merger triangle responsible making arrangements obtain supplies emtricitabine third party anticipated commercial launch following receipt marketing approvals us european union triangle made adequate arrangements supplies supply problems third party manufacturers emtricitabine may sufficient supplies emtricitabine meet commercial demand case future results could suffer triangle entered agreement abbott abbott agreed manufacture emtricitabine bulk drug substance final drug product us transfer manufacturing technology emtricitabine third party manufacturers rely abbott third parties manufacture emtricitabine period time seeking qualification abbott us european union contract manufacturer abbott recent history violations current good manufacturing practice regulations cited fda working towards corrections fda consent decree fda conducted preapproval inspection abbott new drug application emtricitabine issued form observation abbott december january abbott submitted response form observation depend abbott perform obligations effectively timely basis fda deems abbott 's response form observation inadequate abbott unable supply initial launch quantities emtricitabine timely manner timing emtricitabine launch could impacted event could harm competitive position new manufacturers emtricitabine would also approved regulatory authorities delays approval may rely abbott emtricitabine supplies longer period currently anticipated costs supplies emtricitabine third party manufacturers unacceptably high results operations would suffer able arrange manufacture emtricitabine lower cost manufactured emtricitabine sure emtricitabine manufacturing costs reduced acceptable level profitability depend part upon triangle 's operations incurred losses since triangle 's inception triangle incurred losses since inception december accumulated deficit approximately million triangle 's losses resulted primarily expenses associated acquisition development drug candidates general administrative costs triangle generated revenue sale product candidates date expecting triangle 's operations may never generate significant revenue achieve profitability trading price securities could subject significant fluctuations trading price common stock volatile may volatile future factors announcements fluctuations competitors ' operating results changes prospects market conditions biotechnology stocks general could significant impact future trading prices common stock particular trading price common stock many biotechnology companies including us experienced extreme price volume fluctuations times unrelated operating performance companies whose stocks affected factors may cause volatility price securities include clinical trial results regulatory developments quarterly variations results business product market cycles fluctuations customer requirements availability utilization manufacturing capacity timing new product introductions ability develop implement new technologies price securities may also affected estimates projections investment community general economic market conditions cost operations product markets predict individual effect factors may price securities factors either individually aggregate could result significant variations price given period time assurance factors adverse effect trading prices common stock item properties corporate headquarters including principal executive offices research facilities located foster city california location lease approximately square feet space eight proximately located buildings one leases covering approximately square feet space group buildings expires december renewal options remaining leases expire march september option renew leases two additional fiveyear periods also occupy facilities san dimas california location lease approximately square feet space houses research development activities manufacturing certain administrative functions leases expire may november two fiveyear renewal options addition lease adjacent warehouse facility square feet space use product distribution administrative functions lease expires april two additional fiveyear extensions durham north carolina lease approximately square feet administrative office laboratory space sublease approximately square feet third parties lease expires september currently negotiations lessor another lease term addition lease approximately square feet space sales marketing regulatory finance information technology human resource operations europe australia including prepaid year lease square foot manufacturing distribution facility ireland leases various expiration dates believe facilities adequate suitable least current nearterm future needs item legal proceedings reached settlement elan corporation plc successor company liposome company companies agreed dismiss legal proceedings involving ambisome terms initial settlement agreement made initial payment elan million agreed make additional royalty payments based ambisome sales recorded million accounting charge accrued litigation settlement expenses representing net present value future minimum payments required make june entered agreement elan terminating remaining ambisome payment obligations initial settlement agreement exchange payment elan million november ulehi notified us ulehi believes gilead materially breached licensing agreement ulehi concerning selex technology identify aptamers amongst things assigning rights agreement without ulehi 's consent contest ulehi 's allegations met ulehi regarding allegations actively engaged negotiations settle disagreement negotiations prove unsuccessful ulehi chooses terminate ulehigilead agreement arbitration concerning termination would likely result unfavorable outcome arbitration could give rise award us monetary damages adverse remedies possibly including conveyance ulehi gilead 's rights obligations ulehi licensing agreement sublicenses also party various legal actions arose ordinary course business believe legal actions significant impact business item submission matters vote securities holders matters submitted vote securities holders quarter ended december part ii item market registrant 's common stock related stockholder matters common stock traded nasdaq stock market symbol gild following table sets forth periods indicated high low intraday sale prices per share common stock nasdaq stock market prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception anticipate paying foreseeable future december issued million convertible senior notes due december private offering goldman sachs co resold notes qualified institutional investors net proceeds approximately million following table provides certain information respect equity compensation plans effect end fiscal year ended december shares thousands equity compensation plan information number common shares number common remaining available shares weightedaverage issuance equity issued upon exercise price compensation plans exercise outstanding excluding securities outstanding options options warrants reflected warrants rights rights column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes approximately million shares issuable gilead 's employee stock purchase plan see note consolidated financial statements item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement operations data total revenues total costs expenses income loss operations gain sale oncology assets income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amounts per common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharebasic shares used per share calculationbasic amounts per common sharediluted income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharediluted shares used per share calculationdiluted december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible debt accumulated deficit total stockholders ' equity completed sale oncology assets related technology osi pharmaceuticals inc recorded nonoperating gain million also recorded nonoperating gain million sale percent interest proligo gilead sold shares osi common stock recognized loss sale marketable securities million shares partial consideration sale oncology assets gilead sciences inc selected consolidated financial data continued thousands except per share data prior period restated reflect merger nexstar pharmaceuticals inc july accounted pooling interests gilead adopted statement financial accounting standards nos collectively referred sfas accounting derivative instruments hedging activities first quarter change accounted change accounting principle effective first quarter gilead adopted sec 's staff accounting bulletin sab revenue recognition financial statements change also accounted change accounting principle cash dividends declared paid common stock item management 's discussion analysis financial condition results operations overview gilead incorporated delaware june biopharmaceutical company focused discovery development commercialization antivirals antibacterials antifungals treat lifethreatening infectious diseases multinational company revenues six approved products marketing operations ten countries currently market viread tenofovir disoproxil fumarate treatment hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection antifungal agent daunoxome daunorubicin citrate liposome injection drug approved treatment kaposi 's sarcoma vistide cidofovir injection treatment cmv retinitis roche markets tamiflu oseltamivir phosphate treatment influenza collaborative agreement us seeking add existing portfolio products clinical development programs internal discovery programs active product acquisition inlicensing strategy acquisition triangle completed january internal discovery activities include identification new molecular targets target screening medicinal chemistry addition currently developing products treat hiv hbv infections also expertise liposomal drug delivery technology use develop drugs safer easier patients tolerate effective december completed sale oncology assets osi pharmaceuticals inc transaction valued million cash osi stock transaction allow us focus continue strengthen core expertise infectious diseases see note consolidated financial statements information year ended december gilead adopted statement financial accounting standards nos collectively referred sfas accounting derivative instruments hedging activities resulted cumulative effect change accounting principle year ended december gilead adopted securities exchange commission 's staff accounting bulletin revenue recognition financial statements also resulting cumulative effect change accounting principle certain prior period amounts reclassified conform current presentation forwardlooking statements risk factors following discussion contains forwardlooking statements involve risks uncertainties gilead 's actual results could differ materially discussed forwardlooking statements factors could cause contribute differences include limited discussed section well caption business including risk factors affect gilead part forwardlooking statements included document based information currently available gilead include effect acquisition triangle guidance unless specifically noted since still evaluating detailed financial impact triangle 's operations consolidated financial statements assume obligation update forwardlooking statements following discussion read conjunction consolidated financial statements notes included elsewhere report viread sales rely sales viread significant portion operating income number drugs treat hiv infection aids currently sold advanced stages clinical development including products currently sold us among companies significant competitors thehivaids market gsk bms roche pfizer merck boehringeringelheim abbott laboratories given broad range competitors depth resources viread 's market penetration may limited particularly use treatmentnave patients given data supporting viread 's us approval treatmentexperienced patient population ambisome sales also rely sales ambisome significant portion operating income lower priced products compete ambisome two products compete ambisome recently approved us european union products developed could compete ambisome future antifungal products achieve market acceptance antifungal products development become commercially available revenues sales ambisome would likely decrease resulting reduction operating income acquisition integration january completed acquisition triangle acquisition carries inherent risks may able successfully integrate triangle operations obtain anticipated synergies cost savings may also unsuccessful obtaining marketing approval emtricitabine developing coformulated product failure successfully integrate triangle operations business obtain marketing approval emtricitabine could adversely affect financial position results operations market acceptance products ability products achieve sustain market acceptance depend number factors including receipt scope regulatory approvals availability public private insurance reimbursement products safety efficacy tolerability cost products ease administration dosing products compare competitive products products achieve sustain market acceptance results operations suffer regulatory process us food drug administration foreign agencies could reject limit commercialization products number reasons including disagree results designs clinical trials believe products unacceptable efficacy toxicity tolerability believe products manufactured commercial basis compliance applicable safety quality standards agencies reject limit commercialization products financial results would adversely affected clinical trials required regulatory approval products extremely expensive difficult us accurately predict control amount timing expenses quarter quarter addition regulatory agencies could require us conduct additional unanticipated clinical trials products cost could substantial governmental legislation reimbursement programs regulatory legal legislative issues may adversely affect pricing sales products us federal legislation lowers price products purchased reimbursed federal agencies states enacted legislation lower prices products addition growing number us federal state legislative proposals enacted would lower price products many countries outside us government sponsored health care programs set lower drug prices patient reimbursement levels sales countries relatively higher prices may reduced products imported countries lower price markets particular concern european union required permit cross border sales could concern us legislation easing import restrictions enacted applied international credit risk subject credit risk accounts receivable related european product sales european product sales government owned supported customers greece spain portugal italy subject significant payment delays due government funding reimbursement practices significant changes occur reimbursement practices european governments government funding becomes unavailable financial position results operations would adversely affected compulsory licensing generic competition number developing countries government officials groups suggested pharmaceutical companies make drugs hiv infection available low cost cases governmental authorities indicated pharmaceutical companies patents might enforceable prevent generic competition major pharmaceutical companies greatly reduced prices hiv drugs certain developing countries certain countries permit enforcement patents sales viread countries could reduced generic competition alternatively governments countries could require grant compulsory licenses allow competitors manufacture sell versions viread countries thereby reducing viread sales could respond governmental concerns reducing prices viread situations results operations could adversely affected collaborations depend collaborations development commercialization certain products revenue including collaboration fujisawa sales ambisome us canada collaboration gsk clinical regulatory development commercialization hepsera asia latin america certain territories collaboration roche sales tamiflu worldwide may also seek additional collaborations collaborations could fail number reasons including partners devote sufficient resources development commercialization marketing products disputes arise partners existing collaborations fail financial results would adversely affected foreign currency fluctuations significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition prior january hedge exposure impact fluctuating foreign exchange rates forecasted sales effective january begun use forward contracts hedge percentage forecasted international sales primarily denominated euro currency hedge portion accounts receivable balances denominated foreign currencies minimizes eliminate exposure currency fluctuations date sale recorded date cash collected additionally mitigate impact currency rate fluctuations cash outflows certain foreign currencydenominated raw materials purchases enter foreign exchange forward contracts hedge foreign currencydenominated accounts payable uncertain financial results expect financial results continue fluctuate quarter quarter fluctuations may substantial fluctuations caused many factors beyond control including risk factors listed december accumulated deficit million critical accounting policies estimates gilead 's discussion analysis financial condition results operations based upon consolidated financial statements prepared accordance accounting principles generally accepted united states preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosure assets liabilities ongoingbasis evaluate estimates including related revenue recognition bad debts inventories accrued clinical preclinical expenses contingencies base estimates historical experience various market specific assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results however may differ significantly estimates gilead believes following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements record estimated reductions revenue expected returns expired products medicaid reimbursements customer incentives cash discounts prompt payment estimates medicaid reimbursements cash discounts based contractual terms expectations regarding utilization rates programs estimates product returns including new products based ongoing analysis industry historical return patterns expected returns marketed drugs generally low shelf life products ranges months viread months ambisome us conditions become competitive markets served drugs circumstances change may take actions increase product return estimates may offer additional customer incentives would result incremental reduction future revenue time return estimate changed incentives offered also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required write inventory based quality control reviews individual raw material batches generally maintain inventory reserves based estimated obsolescence risk competition primarily shelf life products long however current assumptions future demand competition change actual market conditions less favorable projected management additional inventory reserves may required record accruals estimated clinical preclinical study costs costs significant component research development expenses management accrues costs clinical studies performed contract research organizations based estimates generally work upfront costs remaining activity occurring straightline basis life individual contract study estimate may may match actual services performed organizations determined patient enrollment levels related activities monitor patient enrollment levels related activity extent possible however management underestimated activity levels associated various studies given point time would record additional research development expenses future periods could significant results operations revenues total revenue million million million included total revenue net product sales royalty income contract revenue including revenue research development rd manufacturing collaborations net product sales revenue million compared million million product sales increased compared primarily due significant increases sales viread approved sale us october european union february significant percentage gilead 's product sales continue denominated foreign currencies prior hedge exposure impact fluctuating foreign exchange rates forecasted sales effective january began use forward contracts hedge percentage forecasted international sales reduce eliminate fluctuations sales due changes foreign currency exchange rates primarily denominated euro currency losses revenue hedges reduced product revenues million sales viread million total product sales compared million total product sales viread sales million us sales million international sales continued market expansion viread expect viread sales approximately double range million million sales ambisome million increase ambisome sales million sales ambisome million prior revenues primarily derived sales ambisome represented total product sales total product sales total product sales excluding impact foreign currencies relative us dollar ambisome sales grew year ended december comparable period increase sales compared primarily due volume sales increases europe offset declining sales us increase sales compared primarily due volume price increases us europe addition excluding impact decline foreign currencies relative us dollar sales ambisome would increased expected increase competition expect ambisome sales lower range million million recorded royalty revenue million compared million million threeyear period significant source royalty revenue sales ambisome us fujisawa copromotion arrangement us royalty revenue fujisawa million compared million million also recorded royalty revenue million million million related sales tamiflu tamiflu orally administered compound developed treat prevent viral influenza humans gilead codeveloped tamiflu roche owns worldwide commercial rights tamiflu required pay us royalty net sales product began recognizing royalties tamiflu first quarter june roche received european regulatory approval tamiflu treatment influenza adults children prevention adolescents adults difficult toestimate third party product sales record royalty revenue one quarter arrears total contract revenue million compared million million primary source contract revenue licensing selex process patent estate archemix due collectibility concerns recognized cash basis provided million contract revenue million roche made milestone payments million european prophylaxis treatment approvals tamiflu made million milestone payment relating development tamiflu rd collaboration agreement contract revenue roche consisted million milestone payments related roche completing regulatory filings approvals tamiflu us japan december gilead entitled additional milestone payments million upon roche achieving certain developmental regulatory milestones april gilead gsk entered licensing agreement providing gsk rights commercialize hepsera gilead 's antiviral treatment chronic hepatitis b asia latin america certain territories agreement gilead retained rights hepsera us canada eastern western europe australia new zealand gsk received exclusive rights develop hepsera solely treatment hepatitis b territories significant include china korea japan taiwan addition gsk paid gilead upfront licensing fee million first payment additional obligations may pay million upon achievement gsk certain regulatory development commercial milestones million million received us approval hepsera september gsk also pay gilead royalty net sales hepsera gsk territories gsk full responsibility development commercialization hepsera gsk 's territories million upfront fee million us approval fee recorded deferred revenue total million recognized contract revenue balance deferred revenue december amortized contract revenue period gilead 's remaining obligations agreement approximately years december completed sale oncology assets osi date received million cash million osi stock agreement entitled additional payments osi million either cash combination cash osi stock osi reaches certain development milestones nx advanced oncology product candidates sold osi related manufacturing agreement produce nx gs l two liposomal products included sale manufacturing facility san dimas california recognized million contract revenue manufacturing agreement october entered agreement archemix corporation relating selex technology agreement gave archemix exclusive rights selex process including therapeutic commercial applications extent already licensed preexisting agreements archemix paid us million million required license agreement ulehi paid million million payments ulehi also received warrant purchase shares archemix common stock value material required license agreement ulehi transferred warrant ulehi march entered agreement eyetech pharmaceuticals inc relating gilead 's proprietary aptamer eye currently known macugen currently early clinical trials macugen inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses macugen product successfully commercialized eyetech pay us royalties worldwide sales product eyetech also responsible research development costs provided clinical supplies product eyetech march received million upfront licensing fee eyetech april recognized revenue ratably oneyear supply agreement period accordingly million license fee recorded contract revenue million recognized revenue also entitled additional cash payments eyetech million eyetech reaches certain macugen development milestones additionally received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors gross margins product gross margins compared improvement primarily driven product mix viread higher margin product contributed significantly net product sales whereas modest sales viread recorded foreign exchange also impacts gross margins price products currency country products sold significant majority manufacturing costs us dollars example increase value foreign currencies relative us dollar positively impact gross margins since manufacturing costs remain approximately revenues translated us dollars increase gross margins positively impacted weakening us dollar gross margins negatively impacted factors discussed product sales section caption revenues except potential impact unpredictable uncontrollable changes exchange rates relative us dollar mix product sales viread hepsera ambisome expect gross margins remain relatively stable compared operating expenses rd expenses total costs expenses total rd expenses million compared million million major components rd expenses consist personnel costs including salaries benefits clinical studies performed contract research organizations materials supplies overhead allocations consisting various support facilities related costs rd activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology work clinical development costs include phase clinical trials well expanded access programs pharmaceutical development costs consist product formulation chemical analysis following table breaks major components research development spending thousands research clinical development pharmaceutical development oncology divested total million decrease rd spending compared primarily due reduction expenses associated clinical program viread approved october elimination expenses associated oncology program result sale oncology program osi december additionally recognized expense million million upfront license fee paid cubist pharmaceuticals related european licensing agreement daptomycin also known cidecin signed january upon termination agreement september million recorded rd represented remaining unamortized asset related preclinical oral formulation daptomycin excluding impact triangle acquisition expect rd expenses approximately million million approximately higher expenses million increase rd spending versus attributable part recognition million million upfront payment million clinical milestone payments cubist european licensing agreement cidecin addition expenses associated clinical programs viread hepsera increased approximately million million respectively year recent industry reports indicate biopharmaceutical company generally takes years average years research develop bring market new prescription medicine us averages generally consistent projects develop internally although recent product development timelines accelerated basis drug development us process includes several steps defined fda process begins filing ind successful allows opportunity clinical study potential new medicine clinical development typically involves three phases study phase generally accounts average seven years drug 's total development time significant costs associated clinical development phase trials tend longest largest studies conducted drug development process currently products development phase studies successful development products highly uncertain estimation completion dates rd expenses vary significantly product difficult predict even successful development fda approval product undertake additional studies try expand product 's label market potential complete discussion risks uncertainties associated completing development products see risk factors affect gilead section item selling general administrative sga expenses million compared million million increase expenses compared primarily due global sales marketing efforts including expansion gilead 's us european sales forces support commercial launches viread hepsera increase sga expenses versus primarily due gilead 's increased global marketing efforts expansion sales force support commercial launch viread expect sga expenses excluding impact triangle acquisition approximately million million higher levels primarily due increase marketing activities associated continued promotion viread hepsera ambisome gain sale oncology assets december completed sale oncology assets pipeline clinical stage oncology products related intellectual property well boulder colorado operations including clinical research drug development personnel infrastructure facilities osi pipeline clinical candidates includes nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor closing date received million cash osi common stock valued approximately million recorded nonoperating gain million fourth quarter result transaction addition recorded income taxes million connection transaction loss sale marketable securities july company sold remaining shares osi common stock approximately million shares partial consideration sale oncology assets osi december time recorded fair market value approximately million connection sale remaining shares recognized nonoperating loss approximately million year ended december gain sale unconsolidated affiliate august also sold percent interest proligo llc proligo degussa corporation million cash proligo joint venture gilead skw americas inc focused manufacturing oligonucleotides skw americas subsidiary degussa corporation held remaining percent proligo proceeds net gilead 's investment proligo reflected million gain sale unconsolidated affiliate interest income interest expense recorded interest income million compared million million decrease compared attributable significant decline interest rates partially offset higher average cash balance due positive cash flow operations proceeds sale oncology assets osi increase due higher average balances invested funds interest income depend principally upon prevailing interest rates control level cash cash equivalent marketable securities balances incurred interest expense million compared million million significant increase due full year interest million convertible subordinated notes interest expense consisted primarily interest million convertible notes converted common stock august expect interest expense increase compared expense levels primarily due issuance million convertible senior notes december income taxes provision income taxes million million million respectively income tax expense primarily associated income earned foreign subsidiaries significant net operating losses reduce us tax liability significant increase income tax expense resulted principally gain sale oncology assets osi recorded approximately million federal state alternative minimum taxes provision reduced change us income tax law law allows net operating loss carryforward deductions offset alternative minimum taxable income resulting reduction us income tax recorded previous years million record valuation allowance reduce deferred tax assets amount likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance determined would able realize part deferred tax assets future adjustment deferred tax asset would increase income period determination made likewise determine would able realize part deferred tax asset future adjustment deferred tax asset would charged income period determination made evaluate realizibility deferred tax assets quarterly basis equity loss unconsolidated affiliate recorded million equity loss unconsolidated affiliate proligo prior date sale percent interest recorded million equity loss proligo represented percent share proligo 's loss thirteenmonth period ended december fourth quarter proligo changed fiscal yearend december november cumulative effect change accounting principle year ended december gilead adopted sfas accounting derivative instruments hedging activities resulted cumulative effect change accounting principle million year ended december gilead adopted securities exchange commission 's staff accounting bulletin revenue recognition financial statements resulting cumulative effect change accounting principle million see notes consolidated financial statements discussion liquidity capital resources fourth quarter misclassification discovered december balance sheet cash flow statement year ended december million osi stock received consideration divestiture oncology assets misclassified balance sheet cash cash equivalents instead marketable securities misclassification impact statement operations period including revenues net income december consolidated balance sheet consolidated statement cash flows report changed reflect correct classification cash cash equivalents marketable securities totaled million december million december increase million primarily due million net proceeds received issuance convertible senior notes december major sources uses cash included net cash provided operations million proceeds issuances stock employee stock plans million partially offset capital expenditures million million convertible note received triangle million loan triangle returned us connection completed acquisition january approximately million paid complete acquisition triangle working capital december million compared million december significant changes working capital included million increase accounts receivable million increase inventory accounts receivable increase primarily due increased sales viread us europe million increase inventory primarily due increase production viread inventory meet increasing sales demand significant changes current liabilities included million increase accrued liabilities million decrease accrued clinical preclinical expenses million increase accrued compensation million increase accounts payable million increase deferred revenue million increase accrued liabilities primarily due medicaid rebate obligations associated higher sales viread million decrease accrued clinical preclinical expenses primarily due decreasing activity associated clinical trial programs viread hepsera million increase accrued compensation primarily due increased bonus accruals expansion sales force million increase accounts payable primarily due increases raw material purchases support viread sales growth million increase deferred revenue primarily relates million received collaboration gsk entered april million effect exchange rate changes cash primarily due weakening us dollar relative euro translation foreign subsidiaries ' accounts receivable balances primarily denominated euro currency made capital expenditures million million million expenditures primarily facilities improvements accommodate growth well laboratory manufacturing equipment capital expenditures related research development million spent million spent expect capital spending significantly higher levels due increased infrastructure needs higher rd spending december issued million convertible senior notes due december private offering notes currently convertible total shares gilead common stock per share conversion price higher gilead 's common stock price notes ' issuance date notes redeemable whole part option time june specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes december issued million convertible subordinated notes due december private offering notes currently convertible total shares gilead common stock per share conversion price higher gilead 's common stock price notes ' issuance date notes redeemable whole part option time december specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notesin august redeemed convertible subordinated debentures cash price per principal amount debentures outstanding plus accrued interest redemption price provided original debenture indenture upon redemption entire million principal amount debentures outstanding time converted newly issued shares gilead common stock august deferred debt issuance costs million related debentures charged additional paid capital connection conversion debentures common stock believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including commercial performance viread hepsera ambisome commercial performance products development receive marketing approval including emtricitabine acquisition triangle completed january success partners ' research development commercialization efforts products partnered us progress research development efforts scope results preclinical studies clinical trials cost timing outcome regulatory reviews rate technological advances determinations commercial potential products development administrative expenses status competitive products establishment manufacturing capacity thirdparty manufacturing arrangements expansion sales marketing capabilities possible geographic expansion establishment additional collaborative relationships companies may future require additional funding could form proceeds equity debt financings additional collaborative agreements corporate partners funding required assure available favorable terms subsidiaries established variety subsidiaries various countries purpose conducting business locations subsidiaries consolidated financial statements special purpose entities unconsolidated financial statements including defined variable interest entities financial accounting standards board fasb interpretation consolidation variable interest entities also involved nonexchange traded commodity contracts accounted fair value commercial commitments related parties except employee loans contractual obligations form capital operating leases notes payable clinical research organization contracts recent accounting pronouncements june fasb issued sfas accounting costs associated exit disposal activities sfas requires liability costs associated exit disposal activity recognized measured initially fair value liability incurred sfas effective exit disposal activities initiated december adoption sfas expected material impact financial position results operations november eitf reached consensus issue addressing account arrangements involve delivery performance multiple products services andor rights use assets revenue arrangements multiple deliverables divided separate units accounting deliverables arrangement meet following criteria delivered item value customer standalone basis objective reliable evidence fair value undelivered items delivery undelivered item probable arrangement consideration allocated among separate units accounting based relative fair values amount allocated delivered item limited amount contingent delivery additional items meeting specified performance conditions final consensus applicable agreements entered fiscal periods beginning june early adoption permitted reviewing provisions consensus determine effect may company 's financial position results operations november fasb issued interpretation fin guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others fin elaborates existing disclosure requirements guarantees including residual value guarantees issued conjunction operating lease agreements also clarifies time company issues guarantee company must recognize initial liability fair value obligation assumes guarantee must disclose information interim annual financial statements initial recognition measurement provisions apply prospective basis guarantees issued modified december disclosure requirements effective financial statements interim annual periods ending december adoption disclosure provisions fin material impact results operations financial position december fasb issued sfas accounting stockbased compensationtransition disclosure sfas amendment sfas accounting stockbased compensation issued october sfas provides alternative methods transition voluntary change fair value based method accounting stockbased compensation addition statement amends disclosure requirements statement require prominent disclosures annual interim financial statements method accounting stockbased employee compensation effect method used reported results additional disclosure requirements sfas effective fiscal years ending december elected continue follow intrinsic value method accounting prescribed accounting principles board opinion apb accounting stock issued employees account employee stock options item quantitative qualitative disclosures market risk foreign currency exchange risk operations include manufacturing sales activities us well sales activities europe australia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes exchange rates us dollar various foreign currencies significant euro british pound australian dollar us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business mitigate impact changes currency exchange rates cash flows foreign currency sales transactions enter foreign exchange forward contracts hedge foreign currencydenominated accounts receivable additionally mitigate impact currency rate fluctuations cash outflows certain foreign currencydenominated raw materials purchases enter foreign exchange forward contracts hedge foreign currencydenominated accounts payable significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition prior hedge exposure impact fluctuating foreign exchange rates forecasted sales effective january begun use forward contracts hedge percentage forecasted international sales primarily denominated euro currency following table summarizes notional amounts average currency exchange rates fair values open foreign exchange forward contracts december contracts maturities one year less one exception one hedge contract intended hedge raw materials purchases first quarter notional amount million insignificant fair value december maturity months average rates stated terms amount foreign currency per us dollar fair values represent estimated settlement amounts december notional amounts fair values us dollars thousands fair value currency notional amount average rate december british pound euro total notional amount million fair value million open foreign exchange forward contracts december compares total notional amount million fair value million open foreign exchange forward contracts december interest rate risk portfolio availableforsale investment securities fixedrate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based duration industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestbearing assets fixedrate liabilities december dollars thousands years ending december fair value december thereafter total assets availableforsale securities average interest rate liabilities longterm obligations including current portion average interest rate convertible senior debentures interest rate convertible subordinated debentures interest rate longterm obligations consist capital leases operating leases net noncancelable subleases debt secured property plant equipment interest portion payments due included international credit risk accounts receivable balance december million compared million december growth primarily due higher product sales viread us europe certain countries payments typically slow primarily greece spain portugal italy accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece spain portugal italy totaled approximately million approximately million days past due december past due receivables countries million approximately million days past due date experienced significant losses respect collection accounts receivable believe accounts receivable balances reflected consolidated balance sheet including due customers four countries collectible continually seek improve collection processes ensure fully collect amounts due us based product sales collections timely item financial statements supplementary data financial statements required item set forth beginning report incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable part iii item directors executive officers registrant information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed sec pursuant regulation connection annual meeting proxy statement headings nominees executive officers compliance section securities exchange act item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee report item security ownership certain beneficial owners management information required item incorporated reference section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions information required item incorporated reference sections proxy statement headings compensation committee interlocks insider participation certain transactions executive compensation item controls procedures within days prior date report carried evaluation supervision participation principal executive officer andprincipal financial officer effectiveness design operation disclosure controls procedures based evaluation principal executive officer principal financial officer concluded disclosure controls procedures effective timely alerting material information required included periodic reports securities exchange commission noted design system controls based part upon certain assumptions likelihood future events certain design succeed achieving stated goals potential future conditions regardless remote significant changes internal controls factors could significantly affect controls subsequent date last evaluation part iv item exhibits financial statement schedules reports form k following documents filed part index list financial statements report ernst young llp independent auditors report independent accountants audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders ' equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc dated november agreement plan merger among registrant simbolo acquisition sub inc whollyowned subsidiary registrant triangle pharmaceuticals inc dated december amended restated certificate incorporation registrant amended bylaws registrant amended restated march reference made exhibit exhibit amended restated rights agreement dated october registrant chasemellon shareholder services llc agreement plan merger dated february among registrant gazelle acquisition sub inc nexstar pharmaceuticals inc indenture dated december registrant chase manhattan bank trust company national association including therein forms notes indenture dated december registrant jp morgan trust company national association including herein forms notes registration rights agreement dated december registrant goldman sachs co form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees registrant 's incentive stock option plan related agreements registrant 's supplemental stock option plan related agreements registrant 's employee stock purchase plan amended march registrant 's stock option plan amended restated april amended january amended january form nonqualified stock option issued certain executive officers directors vintage park research development net lease registrant vintage park associates dated march premises located b lakeside drive foster city california related addendum exhibits amendments letter agreement dated september registrant iocbrega exhibits certain confidential information omitted vintage park research development net lease registrant vintage park associates dated september premises located lakeside drive foster city california related exhibits amendment agreement dated october registrant iocbrega related license agreements exhibits certain confidential information omitted amendment agreement dated december registrant iocbrega loan agreement dated october among registrant mark l perry melanie p pea registrant 's nonemployee directors ' stock option plan amended january amended january vintage park research development lease registrant wcb sixteen limited partnership dated june premises located lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limited partnership dated june premises located lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limited partnership dated june premises located b lakeside drive foster city california license supply agreement registrant pharmacia upjohn sa dated august certain confidential information omitted development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc dated september certain confidential information omitted amendment vintage park research development lease registrant spieker properties lp dated august premises located lakeside drive foster city california nexstar pharmaceuticals inc 's incentive stock plan adopted february amended nexstar pharmaceuticals inc 's director option plan adopted july vestar inc stock option plan lease dated march vestar inc majestic realty co patrician associates inc amendment thereto amendment thereto dated june third amendment dated january majestic realty co patrician associates inc registrant lease dated march vestar inc majestic realty co patrician associates inc assignment royalty agreement dated december effective june vestar inc city hope national medical center license agreement effective august vestar inc regents university california agreement fujisawa usa inc vestar inc dated august amendment thereto dated may amendment agreement fujisawa usa inc vestar inc dated april fujisawa usa inc vestar inc certain confidential information omitted amendment agreement fujisawa usa inc registrant dated march agreement fujisawa usa inc vestar inc dated august lease dated april vestar inc majestic realty co patrician associates inc first amendment lease dated april majestic realty co patrician associates inc vestar inc amending lease dated april majestic realty co patrician associates inc vestar inc license distribution agreement dated september sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc certain confidential information omitted settlement agreement dated august among nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omitted amendment dated april sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc license distribution agreement dated september sumitomo nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc deferred compensation plan licensing agreement dated april gilead world markets limited glaxo group limited employment agreement dated july gilead sciences inc sharon surreybarbari triangle pharmaceuticals inc stock incentive plan option agreement triangle pharmaceuticals inc daniel g welch dated august license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc compound amdoxovir dapd dated march license agreement triangle pharmaceuticals inc emory university coviracil ftc dated april license agreement triangle pharmaceuticals inc bukwang pharm ind co ltd dated february exclusive license agreement among triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may settlement agreement among triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited dated may amendment license agreement triangle pharmaceuticals inc bukwang pharm ind co ltd dated april first amendment license agreement triangle pharmaceuticals inc emory university dated may first amendment license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc dated july second amendment license agreement triangle pharmaceuticals inc emory university dated july amendment license agreement triangle pharmaceuticals inc bukwang pharm ind co ltd dated september third amendment license agreement triangle pharmaceuticals inc bukwang pharm co ltd dated august supply manufacturing agreement triangle pharmaceuticals inc abbott laboratories dated july settlement exclusive license agreement among triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation dated august second amendment license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc dated august sublease triangle pharmaceuticals inc eli lilly company dated january sublease amendment triangle pharmaceuticals inc eli lilly company dated march second amendment sublease triangle pharmaceuticals inc eli lilly company dated august third amendment sublease triangle pharmaceuticals inc eli lilly company dated february manufacturing supply agreement gilead world markets ltd ppgsipsy sas entered january subsidiaries registrant consent ernst young llp independent auditors consent pricewaterhousecoopers llp independent auditors power attorney reference made signature certification filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended december incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's current report form k filed october incorporated herein reference filed exhibit registrant 's registration statement form amended incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's annual report fiscal year ended march incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's current report form k filed march incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed march exhibit nexstar pharmaceuticals inc 's registration statement form file incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarter ended june incorporated herein reference filed exhibit registrant 's fiscal year ended december incorporated herein reference filed exhibit registrant 's registration statement form amended incorporated herein reference filed exhibit registrant 's fiscal year ended december incorporated herein reference filed exhibit registrant 's current report form k filed january incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's fiscal year ended december incorporated herein reference filed exhibit registrant 's current report form k filed december incorporated herein reference filed exhibit registrant 's registration statement form filed january incorporated herein reference filed exhibit registrant 's registration statement form filed january incorporated herein reference filed exhibit triangle pharmaceuticals inc 's registration statement form amended incorporated herein reference filed exhibit triangle pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed exhibit triangle pharmaceuticals inc 's quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals inc 's quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals inc 's current report form k filed september incorporated herein referencefiled exhibit triangle pharmaceuticals inc 's current report form k filed september incorporated herein reference filed exhibit triangle pharmaceuticals inc 's quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals inc 's fiscal year ended december incorporated herein reference certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary sec without mark pursuant registrant 's application requesting confidential treatment rule b securities exchange act b reports form k registrant filed report form k december regarding tender offer purchase outstanding common shares triangle pharmaceuticals inc price per share registrant filed reports form k december december regarding sale million convertible notes million overallotment exercised full rule offering qualified institutional buyers gilead sciences inc consolidated financial statements years ended december contents report ernst young llp independent auditors report independent accountants audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders ' equity consolidated statements cash flows notes consolidated financial statements report ernst young llp independent auditors board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders ' equity cash flows three years period ended december audits also included financial statement schedule listed item annual report financial statements schedule responsibility management gilead sciences inc responsibility express opinion financial statements schedule based audits audit financial statements proligo llc limited liability company investment reflected accompanying consolidated financial statements using equity method accounting company 's equity net loss proligo llc financial statements proligo llc audited auditors whose report furnished us opinion insofar relates amounts included proligo llc based solely report auditors conducted audits accordance auditing standards generally accepted united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits report auditors provide reasonable basis opinion opinion based audits report auditors consolidated financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity accounting principles generally accepted united states also opinion financial statement schedule referred considered relation basic financial statements taken whole presents fairly material respects information set forth therein discussed notes consolidated financial statements effective january company changed method accounting derivative instruments hedging activities effective january changed method accounting nonrefundable upfront fees received connection collaboration agreements ernst young llp palo alto californiajanuary report independent accountants board directors members proligo llc opinion accompanying consolidated balance sheets related consolidated statements operations members ' equity cash flows present fairly material respects financial position proligo llc subsidiaries december november results operations cash flows thirteenmonths ended december year ended november period august november respectively conformity accounting principles generally accepted united states america financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion pricewaterhousecoopers llp broomfield colorado january gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents marketable securities accounts receivable net allowance doubtful accounts december december note receivable triangle pharmaceuticals inc inventories prepaid expenses total current assets property plant equipment net noncurrent assets liabilities stockholders ' equity current liabilities accounts payable accrued clinical preclinical expenses accrued compensation employee benefits accrued liabilities deferred revenue longterm obligations due within one year total current liabilities longterm deferred revenue accrued litigation settlement expenses due one year longterm obligations due one year convertible senior debt convertible subordinated debt commitments contingencies see accompanying notes stockholders ' equity preferred stock par value per share issuable series shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december december respectively additional paidin capital accumulated comprehensive income accumulated deficit total stockholders ' equity see accompanying notes gilead sciences inc consolidated statements operations thousands except per share amounts year ended december revenues product sales royalty revenue contract revenue total revenues costs expenses cost goods sold research development selling general administrative total costs expenses income loss operations gain sale oncology assets gain sale unconsolidated affiliate loss sale marketable securities interest income net interest expense income loss provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle provision income taxes equity loss unconsolidated affiliate income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amounts per common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharebasic shares used per share calculationbasic amounts per common sharediluted income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharediluted shares used per share calculationdiluted see accompanying notes gilead sciences incconsolidated statement stockholders ' equity thousands common stock accumulated additional paid comprehensive income total stockholders ' shares amount capital loss deferred compensation accumulated deficit equity balance december net loss unrealized gain availableforsale securities net foreign currency translation adjustment comprehensive loss employee stock purchase plan option exercises net warrant exercises net conversion convertible subordinated debentures amortization deferred compensation compensatory stock transactions balance december net income unrealized gain availableforsale securities net foreign currency translation adjustment unrealized gain cash flow hedges net comprehensive income employee stock purchase plan option exercises net tax benefits employee stock plans amortization deferred compensation compensatory stock transactions balance december net income unrealized loss availableforsale securities net foreign currency translation adjustment unrealized gain cash flow hedges net comprehensive income employee stock purchase plan option exercises net tax benefits employee stock plans compensatory stock transactions balance december see accompanying notes gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income loss adjustments reconcile net income loss net cash provided used operating activities depreciation amortization net effect change accounting principle gain sale oncology assets gain sale unconsolidated affiliate loss sale marketable securities equity loss unconsolidated affiliate net movement provision doubtful accounts tax benefits employee stock plans net unrealized gain loss foreign currency transactions noncash transactions changes operating assets liabilities accounts receivable inventories prepaid expenses assets longterm prepaid royalties accounts payable accrued liabilities deferred revenue net cash provided used operating activities investing activities purchases marketable securities sales marketable securities maturities marketable securities capital expenditures issuance note triangle pharmaceuticals inc proceeds sale oncology assets proceeds sale unconsolidated affiliate investment unconsolidated affiliate net cash provided used investing activities financing activities proceeds issuances common stock repayments longterm obligations proceeds issuance convertible senior notes net issuance costs proceeds issuance convertible subordinated notes net issuance costs net cash provided financing activities effect exchange rate changes cash net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental disclosure cash flow information interest paid income taxes paid noncash investing financing activities osi common stock received upon sale oncology assets common stock issued upon conversion debentures reclassification deferred debt issuance costs additional paidin capital upon conversion subordinated debentures see accompanying notes gilead sciences inc notes consolidated financial statements december organization summary significant accounting policies overview gilead company incorporated delaware june biopharmaceutical company focused discovery development commercialization antivirals antibacterials antifungals treat lifethreatening infectious diseases multinational company revenues six approved products operations ten countries currently market viread treatment hiv infection hepsera treatment chronic hepatitis b infection ambisome antifungal agent daunoxome drug approved treatment kaposi 's sarcoma vistide treatment cmv retinitis roche markets tamiflu treatment influenza collaborative agreement us seeking add existing portfolio products ourclinical development programs internal discovery programs active product acquisition inlicensing strategy acquisition triangle pharmaceuticals inc completed january internal discovery activities include identification new molecular targets target screening medicinal chemistry addition currently developing products treat hiv infection also expertise liposomal drug delivery technology use develop drugs safer easier patients tolerate effective accompanying consolidated financial statements include accounts gilead wholly majorityowned subsidiaries significant intercompany transactions eliminated certain prior period amounts including certain cash cash equivalents marketable securities reclassified consistent current presentation stock split february march gilead completed twoforone stock splits effected form stock dividend stockholders record february february respectively accordingly share per share amounts periods presented reflect splits changes accounting principles gilead adopted statement financial accounting standards sfas nos collectively referred sfas accounting derivative instruments hedging activities first quarter change accounted change accounting principle see note effective first quarter gilead adopted sec 's staff accounting bulletin sab revenue recognition financial statements change also accounted change accounting principle see note critical accounting policies estimates preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosure assets liabilities ongoing basis management evaluates estimates including related revenue recognition bad debts inventories accrued clinical preclinical expenses contingencies base estimates historical experience various market specific assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates revenue recognition recognize revenue product sales persuasive evidence arrangement exists delivery occurred price fixed determinable collectibility reasonably assured provide customers general right product return however accept returns product expired deemed damaged defective delivered provisions made estimated product returns cash discounts government discounts rebates based contractual terms expectations regarding utilization rates programs contract revenue research development recorded earned based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement gilead recognized earlier payments received collection assured revenue nonrefundable upfront license fees milestone payments continue involvement development collaboration obligation supply product recognized manufacturing obligation fulfilled ratably development period period manufacturing obligation appropriate revenue associated substantive performance milestones recognized based upon achievement milestones defined respective agreements revenue research development cost reimbursement contracts recognized related costs incurred advance payments received excess amounts earned classified deferred revenue royalty revenue sales ambisome recognized month following corresponding sales occur royalty revenue sales vistide tamiflu recognized received quarter following quarter corresponding sales occur shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements operations research development expenses major components rd expenses consist personnel costs including salaries benefits clinical studies performed contract research organizations materials supplies overhead allocations consisting various administrative facilities related costs research development activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology work clinical development costs include phase clinical trials well expanded access programs pharmaceutical development costs consist product formulation chemical analysis record accruals estimated clinical preclinical study costs costs significant component rd expenses management accrues costs clinical studies performed contract research organizations based estimates typically work upfront costs remaining activity generally incurred straightline basis life individual contract study estimate may may match actual services performed organizations determined patient enrollment levels related activities monitor patient enrollment levels related activity extent possible adjust estimates line actual activity incurred ongoing basisadvertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million stockbased compensation accordance provisions sfas accounting stockbased compensation company elected continue follow accounting principles board opinion apb accounting stock issued employees interpretation fin accounting certain transactions involving stock compensationan interpretation apb opinion accounting employee stock option plans apb exercise price gilead 's employee director stock options equals exceeds fair value underlying stock date grant compensation expense recognized see note pro forma disclosures stockbased compensation pursuant sfas amended sfas accounting stockbased compensation transition disclosure table presents combined net income loss basic diluted net income loss per common share compensation cost gilead nexstar stock option plans espp determined based estimated fair value awards plans grant purchase date thousands except per share amounts year ended december net income lossas reported deduct total stockbased employee compensation expense determined fair value based method awards net related tax effects pro forma net income loss thousands earnings loss per share basicas reported basicpro forma dilutedas reported dilutedpro forma fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option pricing model used multiple option approach following assumptions year ended december expected life years vesting date stock options espp discount rate stock options espp volatility expected dividend yield weighted average estimated fair value espp shares purchased per share computations basic net income per common share computed based weighted average number common shares outstanding period diluted net income per common share includes effects approximately million stock options include effect million convertible notes would convert approximately million shares million convertible notes would convert approximately million shares effect assumed conversion antidilutive diluted net income per common share includes effects approximately million stock options warrants include effect million convertible notes would convert approximately million shares effect assumed conversion antidilutive basic diluted loss per common share computed based weighted average number common shares outstanding period potential common shares convertible notes stock options warrants well convertible debentures previously outstanding excluded computation diluted loss per share effect would antidilutive cash cash equivalents consider highly liquid investments insignificant interest rate risk remaining maturity three months less purchase date cash equivalents may enter overnight repurchase agreements purchase securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents investment policy may enter repurchase agreements repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold gilead fourth quarter misclassification discovered previously reported december balance sheet cash flow statement atdecember million osi stock received consideration divestiture oncology assets misclassified balance sheet cash cash equivalents instead marketable securities december consolidated balance sheet consolidated statement cash flows report changed reflect correct classification marketable securities management determines appropriate classification marketable securities consists solely debt securities time purchase reevaluates designation balance sheet date marketable securities classified availableforsale carried estimated fair values reported either cash equivalents marketable securities december cash cash equivalents include million securities designated availableforsale million december unrealized gains losses availableforsale securities excluded earnings reported separate component stockholders ' equity interest income includes interest dividends amortization purchase premiums discounts realized gains losses sales securities cost securities sold based specific identification method regularly review investments otherthan temporary declines fair value determine decline fair value investment accounting basis otherthantemporary reduce carrying value securities hold record loss amount decline reductions required past three years concentrations credit risk gilead subject credit risk portfolio cash equivalents marketable securities policy limit amounts invested securities duration industry group investment type issuer except securities issued us government gilead exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return gilead also subject credit risk accounts receivable related product sales significant amount trade accounts receivable arises sales ambisome viread primarily sales european subsidiaries export sales distributors europe certain countries payments typically slow primarily greece spain portugal italy accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece spain portugal italy totaled approximately million approximately million days past due december past due receivables countries million approximately million days past due date experienced significant losses respect collection accounts receivable believe past due accounts receivable reflected consolidated balance sheet including due customers four countries collectible perform credit evaluations customer 's financial condition generally required collateral many materials utilize operations made one facility example depend single suppliers high quality amphotericin b daunorubicin hcl distearoylphosphatidylcholine high quality cholesterol used manufacture one liposomal products supplies suppliers interrupted reason may unable ship viread ambisome hepsera vistide daunoxome supply products development clinical trials december million note receivable triangle pharmaceuticals inc incurred conjunction acquisition completed january note included cash cash equivalents marketable securities subsequently eliminated consolidation result closing acquisition january inventories inventories recorded lower cost market cost determined firstin firstout basis management periodically reviews composition inventory order identify obsolete slowmoving otherwise unsaleable items items observed alternate uses inventory record writedown net realizable value period units identified impaired historically inventory writedowns insignificant consistent management 's expectations property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straight line method estimated useful lives follows description estimated useful life years building leasehold improvements laboratory manufacturing equipment office computer equipment office computer equipment includes capitalized computer software capitalized software purchased internally developed computer software leasehold improvements capitalized leased equipment amortized shorter lease term item 's useful life capitalized interest construction progress included property plant equipment noncurrent assets noncurrent assets december includes million respectively prepaid royalties paid institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega discussed iocbrega caption note also included noncurrent assets december net deferred debt issuance costs million million respectively related million convertible senior notes issued indecember million subordinated convertible notes gilead issued december longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment us food drug administration another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated incomeproducing asset indication impairment confirm comparing estimated future cash flows expected result use asset eventual disposition carrying amount asset estimating future cash flows assets grouped lowest level identifiable cash flows largely independent cash flows generated asset groups sum expected future cash flows undiscounted without interest changes less carrying amount asset impairment loss measured excess carrying value asset fair value recognized cash flow estimates used calculations based management 's best estimates using appropriate customary assumptions projections time foreign currency translation transactions contracts adjustments resulting translating financial statements foreign subsidiaries us dollars excluded determination net income accumulated separate component stockholders ' equity net foreign exchange transaction gains losses reported selling general administrative expense consolidated statements operations realized gains losses million million million hedge certain foreign currency exposures related outstanding trade accounts receivable firmly committed purchase transactions forecasted product sales foreign exchange forward contracts general contracts expose us market risk gains losses contracts offset gains losses transactions hedged exposure credit risk contracts function changes interest currency exchange rates therefore varies time gilead limits risk counterparties contracts may unable perform transacting major us banks also limit risk loss entering contracts provide net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized unrealized gains outstanding contracts ie contracts positive fair value date default enter speculative foreign currency transactions write options presently hedge net investment foreign subsidiaries accounting hedges accounts receivable record changes fair value selling general administrative expense derivative instruments designated hedges fas selectively hedge anticipated currency exposures purchasing forward contracts hedge firmly committed purchases transactions anticipated products sales designated cash flow hedges sfas unrealized gains losses underlying forward contracts recorded comprehensive income recognized earnings forecasted transaction occurs december december net unrealized losses open foreign exchange forward contracts million million respectively losses revenue hedges reduced product revenues million notional amounts forward exchange contracts outstanding million december million december contracts maturities one year less one exception one hedge contract intended hedge raw materials purchases first quarter notional amount million insignificant fair value december maturity months see note discussion derivative financial instruments adoption sfas fair value financial instruments company 's financial instruments consist principally cash cash equivalents marketable securities accounts receivable certain noncurrent assets forward foreign exchange contracts accounts payable longterm obligations convertible notes cash cash equivalents marketable securities forward foreign exchange contracts hedge accounts receivable reported respective fair values balance sheet forward foreign exchange contracts hedge firmly committed purchases recorded fair value net related deferred gain loss resulting reported net balance zero fair value convertible senior notes december million carrying value december million fair value convertible subordinated notes december million fair value december million carrying value end period million fair values december december convertible notes determined obtaining quotes market maker notes management believes remaining financial instruments reported balance sheet amounts approximate current fair values recent accounting pronouncementsin june fasb issued sfas accounting costs associated exit disposal activities sfas requires liability costs associated exit disposal activity recognized measured initially fair value liability incurred sfas effective exit disposal activities initiated december adoption sfas expected material impact financial position results operations november eitf reached consensus issue addressing account arrangements involve delivery performance multiple products services andor rights use assets revenue arrangements multiple deliverables divided separate units accounting deliverables arrangement meet following criteria delivered item value customer standalone basis objective reliable evidence fair value undelivered items delivery undelivered item probable arrangement consideration allocated among separate units accounting based relative fair values amount allocated delivered item limited amount contingent delivery additional items meeting specified performance conditions final consensus applicable agreements entered fiscal periods beginning june early adoption permitted reviewing provisions consensus determine effect may company 's financial position results operations november fasb issued interpretation fin guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others fin elaborates existing disclosure requirements guarantees including residual value guarantees issued conjunction operating lease agreements also clarifies time company issues guarantee company must recognize initial liability fair value obligation assumes guarantee must disclose information interim annual financial statements initial recognition measurement provisions apply prospective basis guarantees issued modified december disclosure requirements effective financial statements interim annual periods ending december adoption disclosure provisions fin material impact results operations financial position december fasb issued sfas accounting stockbased compensationtransition disclosure sfas amendment sfas accounting stockbased compensation issued october sfas provides alternative methods transition voluntary change fair value based method accounting stockbased compensation addition statement amends disclosure requirements statement require prominent disclosures annual interim financial statements method accounting stockbased employee compensation effect method used reported results additional disclosure requirements fas effective fiscal years ending december elected continue follow intrinsic value method accounting prescribed accounting principles board opinion apb accounting stock issued employees account employee stock options cumulative effect change accounting principle december securities exchange commission issued staff accounting bulletin sab revenue recognition financial statements among things sab describes sec staff 's position recognition certain nonrefundable upfront fees received connection collaboration agreements previously recognized nonrefundable technology access fees received connection collaboration agreements revenue received collectibility probable technology transferred effective january gilead changed method accounting fees recognize related manufacturing obligation fulfilled straightline basis term related research development collaboration manufacturing supply arrangement appropriate method best matches effort provided management believes change accounting principle preferable based guidance provided sab cumulative effect change accounting principle recorded fourth quarter retroactively effective january deferred revenue recognized contract revenue remaining term research development manufacturing supply arrangements appropriate year ended december net impact change accounting principle increase net loss million per share loss consists million cumulative effect change january net million related deferred revenue recognized contract revenue year additional million contract revenue recognized remainder million related deferred revenue balance december expected recognized revenue derivative financial instruments january gilead adopted sfas standard requires gilead recognize derivatives either assets liabilities measured fair value company enters foreign currency forward contracts hedge changes fair value monetary assets liabilities denominated nonfunctional currency derivative designated meets definition fair value hedge changes fair value derivative hedged item attributable hedged risk recognized earnings company also enters foreign currency forward contracts generally maturities months less hedge future cash flows related purchase transactions forecasted product sales foreign denominated currencies derivative instruments employed eliminate minimize certain foreign currency exposures confidently identified quantified accordance sfas hedges related anticipated foreign currency purchases raw materials forecasted product sales designated documented inception respective hedge designated cash flow hedges evaluated effectiveness quarterly terms forward contract underlying transaction matched inception forward contract effectiveness calculated comparing fair value contract change forward value underlying hedged item upon adoption sfas recorded fair value million related forward contracts previously reflected balance sheet recognized cumulative transition adjustment comprehensive income million effective component hedge substantially values reported comprehensive income december reclassified earnings within months residual changes fair value instruments ineffectiveness recognized immediately selling general administrative expense ineffectiveness significant gilead holds warrants purchase stock two nonpublic companies warrants net exercise features sfas classified derivative instruments upon adoption gilead recorded fair value one warrants million offsetting adjustment cumulative change accounting principle million loss hedging contracts recognized income statement million increase fair value derivatives recognized comprehensive income december fair value derivatives included comprehensive income material sale oncology assets december gilead completed sale oncology assets pipeline clinical candidates oncology related intellectual property well boulder colorado operations including clinical research drug development operations infrastructure facilities osi three clinical development candidates sold osi nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor consideration gilead received million cash shares osi common stock valued approximately million december number shares issued gilead determined dividing million average closing sale price osi common stock days preceding december also entitled additional payments osi million either cash combination cash osi common stock osi reaches certain development milestones nx advanced oncology product candidates sold osi milestone payments received osi recognized contract revenues upon receipt based upon december net book value oncology assets sold million transaction costs million million related acceleration approximately options purchase gilead common stock realized pretax gain million fourth quarter carrying value transferred assets relates primarily certain property equipment osi assumed gilead 's oncologyrelated clinical preclinical obligations well various lease obligations related manufacturing agreement produce osi liposomal formulations nx gs l two liposomal products sold osi manufacturing facility san dimas ca sale marketable securities july gilead sold remaining shares osi common stock approximately million shares partial consideration sale oncology assets osi december time recorded fair market value approximately million connection sale remaining shares recognized nonoperating loss approximately million reflected results year ended december availableforsale securities following summary availableforsale securities estimated fair values availableforsale securities based prices obtained commercial pricing services thousands gross gross amortized unrealized unrealized estimated cost gains losses fair value december us treasury securities obligations us government agencies corporate debt securities assetbacked securities debt securities total december us treasury securities obligations us government agencies certificates deposit corporate debt securities corporate equity securities assetbacked securities debt securities total debt securities consist primarily money market funds also maintain marketable securities nominal value recorded noncurrent assets december securities net unrealized loss approximately million following table presents certain information related sales availableforsales securities thousands year ended december proceeds sales gross realized gains sales gross realized losses sales december million portfolio marketable securities excluding million assetbacked securities contractual maturity less one year million portfolio contractual maturity greater one year less three years none estimated maturities assetbacked securities exceed three years note receivable december part arrangements contemplated proposed acquisition triangle gilead million loan extended triangle working capital corporate purposes triangle issued gilead unsecured convertible promissory note upon completion triangle acquisition january loan eliminated consolidated results result closing acquisition january see note balance sheet detail thousands december inventories raw materials work process finished goods total property plant equipment net building improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction progress less accumulated depreciation amortization total accrued liabilities accrued medicaid rebates accrued sales marketing expenses liabilities total collaborative arrangements contracts glaxosmithkline april gilead gsk entered licensing agreement providing gsk rights commercialize hepsera gilead 's antiviral treatment chronic hepatitis b asia latin america certain territories agreement gilead retained rights hepsera united states canada eastern western europe australia new zealand gsk received exclusive rights develop hepsera solely treatment hepatitis b territories significant include china korea japan taiwan addition gsk paid us upfront licensing fee million entitled receive additional cash payments million upon achievement gsk certain regulatory development commercial milestones million million received us approval hepsera september gsk also pay gilead royalty net sales hepsera gsk territories gsk full responsibility development commercialization hepsera gsk 's territories million upfront fee million us approval fee recorded deferred revenue total million recognized contract revenue balance deferred revenue december amortized contract revenue period gilead 's remaining obligations agreement approximately years december gilead entered agreement glaxo wellcome gsk giving gilead rights gs l novel antitumor compound gilead developing gs l liposome evaluating preclinical studies agreement gilead exclusive worldwide rights develop commercialize gs l indications malaria gilead paid gsk upfront fee included rd expense december compound assigned osi part sale oncology assets may gilead entered threepart collaboration gsk gsk received nonexclusive right use gilead 's proprietary selex process target validation b gilead received exclusive rights subject gsk 's right elect participate activities develop commercialize nx liposomal formulation gsk 's proprietary topoisomerase inhibitor lurtotecan c gsk acquired shares gilead common stock million private offering december collaboration license agreement modified revised terms agreement gsk waived right participate development commercialization nx right receive royalties giving gilead exclusive rights compound december compound also assigned osi part sale oncology assets cubist pharmaceuticals september gilead cubist pharmaceuticals jointly announced termination licensing agreement commercialization cidecin daptomycin injection oral formulation daptomycin agreement executed january granted gilead exclusive commercialization rights products european countries following regulatory approval terms termination agreement gilead owe future payments cubist cubist reacquired european rights products upon termination million recorded research development expense represented remaining unamortized asset related preclinical oral formulation daptomycin archemixin october entered agreement archemix corporation relating selex technology agreement archemix obtained exclusive rights selex process including therapeutic commercial applications extent already licensed preexisting agreements archemix paid us million million required license agreement university license equity holdings inc ulehi paid million million payments ulehi recognized million million revenue respectively also received warrant purchase shares archemix common stock value material required license agreement ulehi transferred warrant ulehi additional payments due archemix agreement eyetech march gilead entered agreement eyetech pharmaceuticals inc relating proprietary aptamer eye known macugen currently early clinical trials macugen inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses macugen product successfully commercialized eyetech pay us royalties worldwide sales product eyetech also responsible research development costs provided clinical supplies product eyetech march also received million upfront licensing fee eyetech april recognized revenue ratably oneyear supply agreement period accordingly million license fee recorded contract revenue agreement remainder license fee recognized revenue also entitled additional cash payments eyetech million eyetech reaches certain macugen development milestones additionally received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors see note description accounting treatment warrant fujisawa rights market ambisome subject agreement gilead fujisawa healthcare inc successor fujisawa usa inc fujisawa terms fujisawa agreement amended fujisawa gilead copromote ambisome us fujisawa sole marketing rights ambisome canada exclusive marketing rights ambisome rest world provided pay royalties fujisawa connection sales significant asian markets including japan connection us sales fujisawa purchases ambisome gilead cost sales canada fujisawa purchases ambisome cost plus specified percentage fujisawa collects payments sale ambisome us canada receive fujisawa 's gross profits sale ambisome us gross profits include deduction cost goods sold giving us current effective royalty rate approximately fujisawa 's net sales ambisome us connection agreement us fujisawa recorded royalty revenue million million million sumitomo september gilead sumitomo entered agreement pursuant sumitomo agreed develop market ambisome japan terms agreement sumitomo paid us initial million licensing fee less withholding taxes million october million milestone payment less withholding taxes million march sumitomo also required make additional payments us certain clinical commercial milestones met pay us royalties japanese ambisome sales agreement gilead obligated provide certain quantity ambisome sumitomo charge ambisome yet approved marketing japan subsequent cumulative effect change accounting principle recorded effective first quarter resulting adoption sab gilead recognized initial license fee remaining free supply arrangement period net impact change accounting principle sumitomo license increase net loss million cumulative effect change accounting principle charge million contract revenue million related initial licensing fee sumitomo recognized contract revenue million recognized contract revenue remaining million recognized contract revenue roche september gilead entered collaboration agreement roche develop commercialize therapies treat prevent viral influenza roche agreement roche agreement roche received exclusive worldwide rights gilead 's proprietary influenza neuraminidase inhibitors prior roche made license fee developmental milestone payments totaling million gilead recognized million contract revenue milestone payments roche related tamiflu milestones achieved year milestones included filing regulatory approval japan treatment influenza japanese approval application filing us regulatory approval prevention influenza receipt approval us recognized million milestone payment filing application market tamiflu prophylaxis european union recognized million milestone payments european approval tamiflu treatment prophylaxis december gilead entitled additional cash payments roche million upon roche achieving additional developmental regulatory milestones addition roche required pay gilead royalties net product sales gilead began receiving royalties roche 's sales tamiflu first quarter recorded total million tamiflu royalties million royalties million royalties recognize royalty revenue roche quarter following quarter related tamiflu sales occur roche agreement roche also reimburses us related rd costs program funding costs quarterly generally advance based annual budget reimbursements included contract revenue incur related rd costs amounts incurred us excess amounts funded may also reimbursed subject roche 's approval event revenue recognized approval obtained conversely amounts funded roche exceed related rd costs may required repay excess funding roche recorded contract revenue rd reimbursements related roche agreement approximately million previous three years ending rd costsrelated roche agreement approximate reimbursement revenue included rd expenses pharmacia august gilead pharmacia corporation pharmacia entered license supply agreement pharmacia agreement market vistide countries outside us terms pharmacia agreement pharmacia paid gilead initial license fee million subsequent cumulative effect change accounting principle recorded effective first quarter gilead recognizing initial license fee straightline basis supply arrangement period sixteen years agreement date net impact change accounting principle pharmacia agreement increase net loss million cumulative effect change accounting principle related initial license fee pharmacia million charge results operations additional contract revenue million recognized subsequent accounting change remaining million related deferred revenue expected recognized straightline basis contract revenue remaining supply period terms pharmacia agreement related agreements covering expanded access programs vistide outside us gilead responsible maintaining cidofovir patent portfolio supplying pharmacia bulk cidofovir used manufacture finished vistide product gilead entitled receive royalty based upon pharmacia 's sales vistide gilead receives portion royalty upon shipping either bulk drug substance vistide pharmacia remainder upon pharmacia 's sale vistide third parties royalties gilead receives product sold third parties recorded deferred revenue thirdparty sales occur december recorded balance sheet approximately million deferred revenue million december recognized royalty revenue sales vistide outside united states pharmacia million million million somalogic november gilead somalogic inc somalogic entered agreement whereby gilead assigned somalogic sole exclusive license certain intellectual property related selex process diagnostic purposes including patents patent applications terms agreement somalogic required pay gilead total million two nonrefundable installments first million paid november included contract revenue year ended december remaining million reported deferred revenue december received recorded contract revenue gilead ongoing research funding obligations agreement iocbrega gilead entered agreements institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega relating certain nucleotide compounds discovered two institutions agreements gilead received exclusive right manufacture use sell nucleotide compounds gilead obligated pay iocbrega percentage net revenues received sales products containing compounds subject minimum royalty payments products covered agreement include vistide hepsera viread exclude tamiflu gilead currently makes quarterly payments iocbrega based percentage vistide hepsera viread sales december agreements iocbrega amended provide reduced royalty rate future sales hepsera viread return front payment gilead million upon signing agreement payment recorded longterm prepaid royalty classified noncurrent assets balance sheet december recognized royalty expense expected commercial life viread hepsera amortization million payment began product launch dates viread hepsera totaled million december southern research institute december gilead entered agreement southern research institute giving gilead worldwide rights develop commercialize gs antitumor compound gilead evaluating preclinical studies terms agreement gilead paid southern research institute upfront fee included research development expense december compound assigned osi part sale oncology assets investment sale unconsolidated affiliate july established proligo llc delaware limited liability company proligo wholly owned subsidiary transferred assets nexstar technology products division proligo proligo supplies nucleic acid peptide synthesis products pharmaceutical biopharmaceutical industry sale use laboratory research reagents therapeutic diagnostic products august sold interest interest proligo skw americas inc skw payment interest received million cash interest perseptive biosystems gmbh company hamburg germany hamburg company specializes manufacture nucleoside phosphoramidite monomers interest hamburg company fair market value approximately million recorded million gain connection sale january october gilead made two additional cash investments proligo total million maintain ownership interest proligo gilead commitments provide additional funding proligo beyond january accounted investment proligo using equity method accounting recognized million equity proligo 's net loss representing share proligo 's loss thirteenmonth period ended december fourth quarter proligo changed fiscal year end december november gilead sold interest proligo degussa corporation million cash proceeds net gilead 's investment proligo reflected million gain sale unconsolidated affiliate prior date sale gilead recorded million equity loss proligo longterm obligations longterm obligations consist following thousandsdecember capital lease obligations monthly installments interest rates ranging fixed rate debt monthly installments secured equipment interest rates ranging total longterm obligations less current portion longterm obligations due one year maturities longterm obligations including capital lease obligations follows thousands year ending december less amount representing interest total terms various debt agreements require us comply certain financial operating covenants december compliance covenants convertible notes december gilead issued million convertible senior notes due december private offering goldman sachs co resold notes qualified institutional investors notes convertible total shares gilead common stock per share conversion price higher gilead 's common stock price note 's issuance date notes redeemable whole part option gilead time june specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes december gilead issued million convertible subordinated notes due december private offering jp morgan co lehman brothers morgan stanley dean witter resold notes private institutional investors notes convertible total shares gilead common stock per share conversion price higher gilead 's common stock price note 's issuance date notes redeemable whole part option gilead time december specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities facility leases foster city san dimas california expire various dates leases two fiveyear renewal options exception one lease foster city expires contains renewal options also operating leases sales marketing administrative facilities europe australia various terms equipment leases also include corporate airplane initial term two years annual renewal option ten years lease expense net sublease income operating leases totaled approximately million million million addition assumed facility lease durham north carolina connection acquisition triangle january lease approximately square feet administrative office laboratory space sublease approximately square feet third parties lease expires september currently negotiations lessor extend lease term aggregate noncancelable future minimum rental payments operating capital leases net aggregate future minimum rentals received us noncancelable subleases follows thousandsoperating leases net noncancelable subleases excluding triangle leases years ending december capital leases thereafter less amount representing interest total capital lease obligations less current portion capital lease obligations due one year december placed million bank escrow deposit included noncurrent assets secure aggregate future payments due one facilities leases contingent liability gilead subleased certain facilities primarily california sublessees default obligations subleases would primarily liable original lessor total future amounts due leases december million legal proceedings reached settlement elan corporation plc elan successor company liposome company companies agreed dismiss legal proceedings involving ambisome gilead 's liposomal formulation amphotericin b terms initial settlement agreement made initial payment elan million agreed make additional royalty payments based ambisome sales recorded million accounting charge accrued litigation settlement expenses representing estimated net present value future minimum payments required make june elan gilead entered agreement terminating remaining ambisome payment obligations initial settlement agreement exchange payment elan million excess million settlement amount remaining accrued litigation settlement expenses balance million amortized remaining life patents approximately four years november ulehi notified us ulehi believes gilead materially breached licensing agreement ulehi concerning selex technology identify aptamers amongst things assigning rights agreement without ulehi 's consent contest ulehi 's allegations met ulehi regarding allegations actively engaged negotiations settle disagreement negotiations prove unsuccessful ulehi chooses terminate ulehigilead agreement arbitration concerning termination would likely result unfavorable outcome arbitration could give rise award us monetary damages adverse remedies possibly including conveyance ulehi gilead 's rights obligations ulehi licensing agreement sublicenses also party various legal actions arose ordinary course business believe legal actions material adverse impact business results operations financial position stockholders ' equity preferred stock gilead shares authorized preferred stock issuable series board directors board authorized determine designation powers preferences rights series reserved shares preferred stock potential issuance preferred share purchase rights plan preferred stock outstanding december employee stock purchase plan gilead 's employee stock purchase plan espp employees purchase shares gilead common stock based percentage compensation purchase price per share must equal least lower percent market value date offered date purchased total shares common stock reserved issuance espp december shares total shares reserved issued espp shares december stock option plans december gilead adopted incentive stock option plan supplemental stock option plan issuance common stock employees consultants scientific advisors april board approved granting certain additional nonqualified stock options terms conditions substantially similar granted supplemental stock option plan none options issued plans described exercise prices less fair value underlying stock date grant options vest five years pursuant formula determined board expire ten years shares available grant future options plans november gilead adopted stock option plan plan issuance common stock employees consultants options issued plan shall discretion board either incentive stock options nonqualified stock options may plan amended exercise price stock options must least equal fair value gilead 's common stock date grant options vest five years pursuant formula determined board expire ten years plan amended restated april extend term plan may stockholders approved amendment plan increased total number authorized shares plan december shares available grant future options plan november gilead adopted nonemployee directors ' stock option plan directors ' plan issuance common stock nonemployee directors pursuant predetermined formula exercise price options granted directors ' plan must least equal fair value gilead 's common stock date grant options vest five years date grant quarterly five percent installments expire ten years may stockholders approved amendment directors ' plan increased total number authorized shares plan december shares available grant future options directors ' plan stock plans assumed gilead merger nexstar include stock option plan plan incentive stock plan director option plan collectively nexstar plans options pursuant plan incentive stock plan issued outstanding july converted options purchase gilead common stock result merger remain subject original terms conditions shares available grant future options nexstar plans nexstar 's plan allows certain option holders execute cashless exercises options cashless exercise transaction option holder specifies many shares exercised gilead issues specified number shares less number would required cover exercise price based fair value stock exercise date several option holders performed cashless exercises result option awards considered variable therefore recognized nominal amount compensation expense million million july options outstanding category following table summarizes activity gilead nexstar stock option plans three years period ended december option grants presented table exercise prices less fair value underlying stock grant date shares thousands year ended december weighted weighted weighted average average average exercise exercise exercise shares price shares price shares price outstanding beginning year granted forfeited exercised outstanding end year exercisable end year weighted average fair value options granted following summary gilead options outstanding options exercisable december options thousands options outstanding options exercisable weighted average weighted remaining average weighted options contractual exercise options average range exercise prices outstanding life years price exercisable exercise price total company reserved aggregate shares common stock future issuance equity compensation plans december pro forma disclosures elected follow accounting principles board opinion apb account employee stock options apb compensation expense recognized exercise price employee stock options equals market price underlying stock date grant information regarding net income loss earnings loss per share prepared accordance fas determined accounted employee stock options employee stock purchase plan fair value method prescribed fas earnings loss per share method fas resulting effect net income loss earnings loss per share pursuant fas likely representative effects net income loss earnings loss per share pursuant fas future years due subsequent years including additional grants years vesting table presents combined net income loss basic diluted net income loss per common share compensation cost gilead nexstar stock option plans espp determined based estimated fair value awards plans grant purchase date thousands except per share amounts year ended december net income lossas reported deduct total stockbased employee compensation expense determined fair value based method awards net related tax effects pro forma net income loss earnings loss per share basicas reported basicpro forma dilutedas reported dilutedpro forma fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option pricing model used multiple option approach following assumptions year ended december expected life years vesting date stock options espp discount rate stock options espp volatility expected dividend yield weighted average estimated fair value espp shares purchased preferred share purchase rights plan november adopted preferred share purchase rights plan plan provides distribution preferred stock purchase right dividend share gilead common stock purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group common stock purchase rights permit holders holder purchase gilead common stock discount market price time upon payment specified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed board whole part price per purchase right purchase rights voting privileges attached automatically trade gilead common stock october board directors approved amendment purchase rights plan amendment provided among things increase exercise price right plan extension term plan november october acceleration stock options december completed sale oncology assets osi part transaction accelerated approximately options purchase gilead common stock value million see note discussion comprehensive income loss following reclassification adjustments required avoid doublecounting net realized gains losses sales securities previously included comprehensive income prior sales securities thousands year ended december net gain loss sales securities comprehensive income net unrealized gain loss arising year reclassification adjustment net unrealized gain loss reported comprehensive income loss balance accumulated comprehensive income reported balance sheet consists following components thousands december net unrealized gain availableforsale securities net unrealized gain cash flow hedges net foreign currency translation loss accumulated comprehensive income disclosures segments enterprise related information gilead determined one reportable segment management organized business along functional lines product sales consist following thousands year ended december viread ambisome following table summarizes revenues external customers collaborative partners geographic region revenues attributed countries based location customer collaborative partner thousands year ended december united states united kingdom france spain germany italy switzerland european countries countries consolidated total revenues december net book value property plant equipment million approximately assets located us december net book value property plant equipment million approximately assets located us product sales three distributors accounted approximately total revenues product sales one distributor exceed total revenues product sales one distributor accounted approximately total revenues total revenues fujisawa included product sales royalties approximately total revenues revenues roche including royalties milestone payments reimbursement research development expenses exceed total revenues account approximately total revenues income taxes gilead deferred provision income taxes current provision income taxes consisted following thousands year ended december current provision federal state foreign foreign pretax loss million million million difference provision taxes income amount computed applying federal statutory income tax rate income provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle explained thousands year ended december income loss provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle tax federal statutory rate benefitted unbenefitted losses federal alternative minimum taxes december us federal net operating loss carryforwards million state net operating loss carryforwards million federal net operating loss carryforwards expire various dates beginning utilized state net operating loss carryforwards expire various dates utilized addition federal state tax credit carryforwards approximately million million respectively expire years utilization net operating losses credits may subject annual limitation due ownership change limitations provided internal revenue code similar state provisions annual limitation may result expiration net operating losses credits utilization significant increase income tax expense resulted principally gain sale oncology assets osi recorded approximately million federal state alternative minimum taxes provision reduced change us income tax law law allows net operating loss carryforward deductions offset alternative minimum taxable income resulting reduction us income tax recorded previous years million deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities december follows thousands december net operating loss carryforwards research credits capitalized research development expenses reserves accruals currently deductible net total deferred tax assets valuation allowance net deferred tax assets recognized valuation allowance increased million year ended december decreased million year ended december approximately million valuation allowance december relates tax benefits stock option deductions credited additional paidin capital realized retirement savings planas december gilead maintains one retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code prior january gilead maintained two separate retirement savings plans one plan primarily covered former nexstar employees nexstar plan plan primarily covered gilead 's remaining eligible employees gilead plan nexstar plan employee contributions could exceed eligible annual compensation addition nexstar plan included company match employee contributions maximum contributions annual maximum company match december approximately million representing shares gilead common stock held nexstar plan trust plan participants effective january nexstar plan terminated combined gilead plan shares gilead common stock held nexstar plan subsequently liquidated proceeds deposited various investment options available gilead plan gilead plan employees may contribute eligible annual compensation effective january gilead began making matching contributions gilead plan contribute employee 's first contributions annual maximum match total matching contribution gilead plan million million combined million plans related party transactions december chairman gilead 's board directors senior advisor investment fund owns controlling interest pharmaresearch corporation contract research organization performs services connection clinical studies gilead 's payments pharmaresearch corporation million december part arrangements contemplated proposed acquisition triangle pharmaceuticals inc gilead million loan extended triangle working capital corporate purposes triangle issued gilead unsecured convertible promissory note upon completion triangle acquisition january loan eliminated consolidated results result closing acquisition january see note subsequent events january completed acquisition outstanding stock triangle development stage company triangle active development antiviral drug candidates aggregate preliminary purchase price million including cash paid outstanding stock fair value options assumed estimated direct transaction costs employee termination costs intend account transaction first quarter expect record substantial portion aggregate purchase price inprocess research development expense quarterly results unaudited following table thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues total costs expenses net income loss net income loss per common sharebasic net income loss per common sharediluted st quarter nd quarter rd quarter th quarter total revenues total costs expenses income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amounts per common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharebasic amounts per common sharediluted income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharediluted year ended december gilead adopted sfas reported cumulative effect change accounting principle first quarter diluted net income per common share fourth quarter includes effects stock options million convertible subordinated notes december completed sale oncology assets osi recorded nonoperating gain million fourth quarter result transaction gilead sciences inc schedule ii valuation qualifying accounts additions balance balance beginning charged charged end period expense deductions period year ended december allowance doubtful accounts allowance sales returns valuation allowance deferred tax assets year ended december allowance doubtful accounts allowance sales returns valuation allowance deferred tax assets year ended december allowance doubtful accounts allowance sales returns valuation allowance deferred tax assets charged current tax expense charged deferred tax benefit